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 Abstract 
 
 
Attributes of both the viral glycoprotein and its cellular receptor play key roles in 
determining the outcome of infection. This body of work endeavors to illustrate how 
these two components influence the efficiency of virus infection in in vitro and in vivo 
systems with an emphasis on characterizing the transduction capacity of a novel 
entry-targeting glycoprotein. In previous work, the Moloney murine leukemia virus (MLV) 
envelope glycoprotein (Env) was modified to generate the Sst-RBS glycoprotein. This 
glycoprotein was created by replacing the wild type (WT) receptor binding site (RBS), 
located on the surface subunit (SU) of the Env, with the somatostatin peptide hormone 
sequence SST-14. The modifications resulted in abrogating transduction via the natural 
MLV receptor and redirecting transduction to a family of five somatostatin receptors 
(SSTR). I demonstrate that structural characteristics of the Sst-RBS glycoprotein and the 
intracellular fate of the SSTR receptor influence the infection efficiency of pseudotyped 
MLV and human immunodeficiency virus type 1 (HIV-1) based lentiviral (LV) particles. 
Infection and western blot assays indicate that Sst-RBS retains the structural 
requirements for mediating levels of transduction that are comparable to WT and 
approach within 5-fold that of transduction mediated by vesicular stomatitis virus 
(VSV) G protein when each envelope protein is pseudotyped on MLV particles. To 
address the contribution of receptor characteristics on infection efficiency, HEK 293 cell 
lines stably expressing comparable cell surface levels of SSTR-2, SSTR-3 and SSTR-5; 
which have natural differences in intracellular trafficking; were generated. Infection 
assays revealed that distinctive SSTR subtype-specific destinations correlated with 
observable differences in the level of Sst-RBS MLV and LV transduction. Taken together 
the results of virus binding, internalization kinetics, pH-neutralizing agents, protease 
inhibitor and penetration assays support that SSTR-5 allows a greater level of 
transduction because viruses internalized by this subtype are exposed to more 
permissive intracellular compartments. Specifically, SSTR-5-associated virions are 
directed to compartments that are more favorable to cytosolic penetration of viral cores 
than the compartment(s) to which virions bound to subtypes 2 and 3 are directed; 
possibly due to a more beneficial complement of host cell proteases. These data 
suggested that receptor characteristics such as the intracellular fate of internalized virus-
receptor complexes exert a strong influence on the efficiency of infection. Surprisingly, 
even though the difference in the in vitro transduction capacity of Sst-RBS and VSV G 
pseudotyped LV particles was greater than that of the MLV pseudotypes, the difference 
did not translate to a reduction in in vivo transduction capacity. A pilot study examining 
the feasibility of in vivo transduction demonstrated proof of principle and identified 
regions of the murine brain with endogenous surface expression of SSTRs that were as 
efficiently transduced by Sst-RBS LV as by VSV G LV. 
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 Chapter 1. Introduction * 
 
 
Background 
 
 
Moloney Murine Leukemia Virus  
 
Moloney murine leukemia virus (MLV), a member of the genus gammaretrovirus in 
the family Retroviridae; is an enveloped virus containing two copies of a positive-sense, 
single-stranded RNA genome. An ecotropic retrovirus (RV), Moloney MLV initiates 
infection by binding its host cell receptor mCAT-1 (a mouse cationic amino acid 
transporter) to gain entry into host murine cells [1-3]. This interaction is mediated by the 
surface subunit (SU) of the MLV envelope protein (Env) which contains the receptor 
binding site (RBS). The internalization of MLV-mCAT-1 complexes has been to shown to 
occur independently from classical clathrin-mediated endocytosis by a caveolin-
associated pathway [4-6]. Following endocytic events, host cell cathepsin proteases 
found in the late endosomal compartment cleave the viral Env [7] and trigger 
conformational changes in both the SU and transmembrane (TM) domains of Env that 
allow the TM fusion peptide to mediate fusion between the virus and host cell 
membranes [8]. After the virion core is uncoated and released into the host cytosol a 
pre-integration complex (PIC) is formed which includes (among other components) a 
double stranded DNA copy of the viral RNA, which has been reverse transcribed by the 
viral reverse transcriptase enzyme, and the viral integrase enzyme. The PIC is 
transported into the host cell nucleus while the nuclear membrane is dissolved during 
mitotic events [9, 10] and the integrated DNA, or provirus, becomes a template for the 
generation of new infectious virions by host cell machinery. The entry events of 
lentiviruses (LV) such as human immunodeficiency virus type 1 (HIV-1) involve many of 
the same requirements as MLV with a notable exception that nuclear import of the PIC 
does not rely on host cell mitosis, but rather gains access through nuclear pore 
complexes which allow PIC transport across the intact nuclear membrane. It is generally 
thought that whereas MLV integration occurs only in actively dividing cells, HIV-1 is 
capable of integration in both dividing and non-dividing cells [10]. Consequently, LV is 
considered a more appropriate vector for in vivo gene delivery where a majority of target 
cells are quiescent (i.e, not actively dividing). 
 
 
Targeting Gene Delivery 
 
Since the provirus is integrated into the host cell’s chromosome, RVs and LVs are 
attractive solutions for investigators interested in targeting delivery of therapeutic genes 
to the cell and tissue types most likely to benefit from such therapies. To this end, 
numerous attempts at re-directing the MLV Env to new target cells have been published 
(for reviews see [11, 12]). The most frequently used insertion sites include the 
amino-terminus and the proline-rich region (PRR) of the Moloney MLV SU glycoprotein 
* Adapted with permission.  Li, F., B. Y. Ryu, R. L. Krueger, S. A. Heldt and L. M. 
Albritton.Targeted entry via somatostatin receptors using a novel modified retrovirus 
glycoprotein that delivers genes at levels comparable to those of wild-type viral 
glycoproteins. J Virol, 2012. 86(1): 373-381. 
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 but to date these strategies have remained largely unsuccessful [11-13]. Although the 
chimeric virions were generally able to bind their receptors and internalize, membrane 
fusion was impaired resulting in little to no transduction in target cells lacking the natural 
virus receptor [13-15]. These impairments are more pronounced when ligands are 
inserted in the amino-terminus than in the PRR of the SU [14]. Additionally, altering 
critical residues in the amino-terminus blocks infection at a hemi-fusion point [8]. While 
simple RVs , such as MLV, have found specific uses as vectors for delivering genes in 
cell culture and ex vivo therapies (removing cells from the body and transducing them 
before re-implantation) targeting hematopoietic stem cells [13] they have limited use in 
vivo, however. This is mainly due to the restrictions imposed on them from cell division 
requirements during provirus integration and a capacity to induce oncogenesis through 
unregulated integration events [16]. Strategies utilizing other virus species have been 
developed and involve antibody-based strategies using single-chain fragment variable 
(scFv) fused to the c-terminus of the measles virus hemagglutinin H protein [17-19] or 
the immunoglobulin Fc-binding ZZ domain from Staphylococcus aureus protein A into 
the E1 glycoprotein from Sindbis virus [20]. The in vivo potential for these systems is 
also limited because low levels of viral membrane incorporated glycoproteins occurred 
due to aggregation of the scFv leading to incorrect assembly [21] as well as unstable 
interactions [20] and rapid vector inactivation by compliment [22]. Lentiviral based 
strategies might be more effective for in vivo targeting efforts because they are capable 
of transducing terminally differentiated cells which may no longer be actively dividing. 
Lentivirus vectors pseudotyped with the glycoprotein from amphotropic MLV [23] and the 
vesicular stomatitis virus (VSV) G protein [24], both of which are capable of infecting 
nearly every mammalian cell type, have been widely used for gene delivery [13]. 
However, the broad host ranges of these two proteins do not reflect true targeted 
delivery to specific cell types. 
 
 
Sst-RBS: A Modified MLV Envelope Glycoprotein 
 
A new targeting strategy was devised by previous researchers in this laboratory 
based on structural similarities of the Moloney MLV RBS and a small peptide hormone, 
somatostatin 14 (SST-14) [25]. The resulting modified Env glycoprotein, Sst-RBS, was 
created by replacing the wild type (WT) RBS (residues C73 to C86 of Moloney MLV) 
with the SST-14 sequence and short amino- and carboxy-peptide linker sequences 
(Figure 1-1) [25]. The linker sequences were designed to form rigid structural turns 
directing the SST-14 sequence up and away from the SU, in a manner similar to the 
published structure of the Friend strain of MLV [26]. The modifications that created Sst-
RBS resulted in a switch from the use of mCAT-1 to somatostatin receptors (SSTR) [25], 
a family of multi-membrane spanning G protein-coupled receptors (GPCR). These 
receptors are not entry receptors for any known virus and ordinarily recognize SST-14, 
related ligands and peptide mimetics. Replacing the WT RBS with a ligand that binds a 
human transmembrane receptor has several advantages. First, it has the greatest 
chance of maintaining the virus’s natural mechanism of entry, except of course, that 
infection would occur via the new receptor. Second, it reduces issues related to structure 
that affect protein folding and virion assembly. Lastly, it abolishes the natural murine 
host specificity of the virus generating clear evidence that the virus has been retargeted.  
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Figure 1-1. Schematic of the Sst-RBS and wild-type glycoprotein 
 
Schematic representation of the surface subunit of wild type ecotropic Moloney (WT, 
Top) and Sst-RBS (Bottom) envelope glycoproteins with the locations of the receptor 
binding site (RBS) in WT and the peptide sequence YASAGCKNFFWKTFTSCAYTAS 
containing the SST-14 ligand (underlined) flanked by short peptide linkers. RBD: 
Receptor Binding Domain, PRR: Proline Rich Region, CTD: Carboxy-Terminal Domain. 
 
 
Somatostatin and Its Receptor Family 
 
SST-14 is a small peptide hormone that primarily exerts regulatory effects on cells 
of the endocrine and exocrine systems in mammals and fish. Notably, it inhibits the 
release of other hormones such as growth hormone and somatotropin, functions as a 
neurotransmitter, and has anti-proliferative and cell differentiation actions. Two 
biologically active forms are produced by preproprotein cleavage: a 14 (SST-14) and a 
28 (SST-28) amino acid peptide. The SST-14 cleavage product is most commonly used 
as a receptor agonist; both ligands form a hairpin loop structure stabilized by an internal 
disulfide bond [27]. The sequence FWKT, located at the center of the hairpin, is required 
for functional binding to a family of five multi-membrane spanning GPCRs [28]. The five 
SSTR subtypes: SSTR-1, SSTR-2 (A and B), SSTR-3, SSTR-4, and SSTR-5 can be 
classified into two groups based on structural and pharmacological properties. Group 1 
includes SSTR-2 (A and B), SSTR-3 and SSTR-5 whereas SSTR-1 and SSTR-4 belong 
to Group 2. Group 1, but not Group 2, receptors are capable of binding important SST 
analogues such as octreotide [29] and are more efficiently internalized after agonist 
exposure [30]. Subsets of SSTR monomers, homo- and heterodimers are naturally 
expressed in many cell types; however, the SSTR-2A isoform is the most widely 
distributed [29]. Additionally, SSTRs may heterodimerize with other receptors such a 
dopamine type 2 [31]; epidermal growth factor receptor, ErbB [32] and the mu-opioid 
receptor, MOR1 [33]. Surface expression of SSTRs is abundant in the brain; 
gastrointestinal tract; exo- and endocrine pancreas and pituitary and have been 
identified in multiple tumor types and cell lines [27, 28]. 
 
Despite the gene for each SSTR subtype being located on separate chromosomes, 
the SSTRs display remarkable sequence homology. There is 39-57% homology 
between the five subtypes with most variability occurring in the carboxy-terminal 
cytoplasmic tails and a notable conserved motif located in transmembrane domain VII. 
The SSTR also show 82-99% homology across mammalian species [27]. As would be 
expected based on such similar homology, SSTR subtypes bind SST-14 with 
comparable nanomolar affinities [27, 29]; however, binding affinities between the SSTRs 
and other ligands do vary. For instance, while SSTR-2 and SSTR-3 bind SST-28 with 
similar affinities to SST-14, SSTR-5 has a higher affinity for SST-28 [27, 30]. 
Furthermore, octreotide, a synthetic octapeptide that mimics the agonist effects of the 
natural SST ligand, binds SSTR-2 with a higher affinity than both SSTR-3 and SSTR-5 
3 
 [27, 34]. In addition to the range of ligand-receptor affinities there is also evidence that 
various ligands may change the degree of signaling or endocytosis based on different 
conformations of the ligand-receptor complex [34]. As an example, the non-peptide 
ligand L-779,976 binds to SSTR-2 with the same affinity as SST-14, but is 10 times more 
potent at inhibiting cAMP production (a common measure of SSTR signaling) and yet 
could only produce 70% of SST-induced receptor internalization [35]. These differences 
might be attributable to a relatively large,[27] putative ligand binding pocket which is 
thought to span multiple residues across transmembrane domains III-VII [29]. 
 
 
Intracellular Trafficking of Somatostatin Receptors 
 
A common feature of GPCRs is agonist induced receptor desensitization. Agonist 
binding stimulates GPCR signaling which it is regulated, in part, by phosphorylation of 
intracellular receptor domains. Receptor phosphorylation also recruits β-arrestins. 
Depending on the class of GPCR, β-arrestin may not be stably associated with the 
desensitized receptor complex, thus while the desensitization process generally (but not 
always) involves receptor internalization, β-arrestin might not be internalized with the 
complex. Internalization of the GPCR is followed by receptor degradation or 
resensitization/recycling. These actions allow the cells to correspondingly either 
down-regulate or preserve the amount of unbound receptors on the cell surface during 
prolonged agonist exposure. In some cases, mobilization of intracellular stores quickly 
up-regulates surface receptors. The pattern of phosphorylation and β-arrestin 
recruitment determines the extent of SSTR internalization, resensitization and recycling; 
and depends, to a large degree, on the presence and location of clusters of Ser and Thr 
phosphate acceptor sites [34]. Because the carboxy-terminal cytoplasmic tails differ 
among SSTR subtypes 2, 3 and 5 with respect to the amount and position of putative 
phosphorylation sites and β-arrestin recruitment, so does their method of desensitization 
[30, 36]. As a result, the intracellular fates of the ligand-receptor complexes are also 
distinct (Figure 1-2). 
 
In the absence of agonist, SSTR-2 and SSTR-3 are almost entirely localized at the 
plasma membrane, but a large amount of SSTR-5 can be found in intracellular pools in 
certain cell types [34, 37]. After agonist exposure, phosphorylation of clusters of 
acceptor sites occurs in SSTR-2 and SSTR-3, but these clusters are absent in the 
cytoplasmic tail of SSTR-5. Stable β-arrestin complexes are only associated with 
SSTR-2 and their formation is dependent on G protein-receptor kinase (GRK)-mediated 
phosphorylation. Conversely, β-arrestin is only transiently associated with SSTR-3 and 
SSTR-5. SSTR-2 and SSTR-3 are rapidly internalized in response to β-arrestin 
recruitment, and at early time points both are co-localized with transferrin; a commonly 
used early endosome marker [36]. SSTR-2 is recycled back to the plasma membrane 
through the trans-golgi network (TGN) [30] without any detectable loss of the receptor 
[36]. Various SST analogues are reported to have differing fates when internalized with 
SSTR-2: SST-14 is degraded by cellular peptidases located in the early endosome and 
the cleavage products are subsequently released. Endothelin-converting enzyme-1 
(ECE-1) has been implicated; although treatment with the ECE-1 inhibitor SM-19712 
only partially inhibits SST-14 degradation; indicating other proteases may also be 
responsible. Octreotide, however, is released unaltered from cells [38]. After SST-14 
induced endocytosis of SSTR-3, only a small amount of the receptor is redistributed 
back to the plasma membrane. Most SSTR-3 loses transferrin association as the  
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Figure 1-2. Somatostatin receptor subtypes have different intracellular fates 
 
Following SST-14 ligand-induced receptor internalization, each SSTR subtype is 
trafficked to acidified vesicles. During the process of desensitization, the ligand is 
proteolytically cleaved from SSTR-2 (blue), the receptor is returned to the plasma 
membrane and free ligand is released through the recycling pathway. SST-14 bound to 
SSTR-3 (green) is directed to the lysosomal compartment and both ligand and receptor 
are degraded. The intracellular fate of SSTR-5 (red) is unclear, but it may also be 
recycled back to the cell surface. 
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 process progresses, undergoes ubiquitin-dependent lysosomal degradation and is 
consequently down-regulated in response to prolonged SST-14 exposure [36]. In rat 
insulinoma (RIN) cells expressing SSTR-3, SST-14 colocalizes with the lysosomal 
protease cathepsin D, is degraded in a low pH dependent manner and products are 
released from the cell. In contrast, octreotide is released back into the supernatant intact 
and SSTR-3 is continuously recycled [39]. When SST-14 is internalized with SSTR-5 in 
COS-7 cells, the level of surface SSTR-5 is quickly replenished through a combination of 
mobilization from intracellular pools and receptor recycling while internalized ligand is 
directed to an unidentified perinuclear compartment, possibly lysosomes [37]. From the 
wide range of literature on the subject, it is clear that species, ligand and cell-type 
specific intracellular events make desensitization an extremely dynamic process. 
 
 
Statement of Purpose 
 
Several approaches to modifying viral glycoproteins to address the idea of targeting 
gene delivery have been developed (reviewed in [11-13]). To date, the main approach 
has been to insert ligands and proteins into various regions of virus Env proteins in order 
to redirect the virus to new host cell receptors. This strategy has been ineffective 
because these chimeras remain incapable of triggering the correct conformation 
changes in Env that allow membrane fusion. Creating effective therapeutic viral vectors 
entails generating a virus with the greatest potential for transduction and it is clear that 
the largest barrier to this requirement has been membrane fusion. Attributes of both the 
viral glycoprotein and its cellular receptor play key roles in mediating events such as 
membrane fusion capacity and influence the efficiency of infection. The modifications 
employed during development of the Sst-RBS glycoprotein retain the potential for 
membrane fusion; however, the question remains whether Sst-RBS is useful for 
targeting gene delivery in vivo. The goal of this dissertation is to characterize the 
infection efficiency of the Sst-RBS glycoprotein and demonstrate its potential for 
targeting in vivo gene delivery.  
 
• The objective of Chapter 3 is to demonstrate that characteristics of the Sst-RBS 
glycoprotein influence infection efficiency by evaluating the structural 
requirements of the SST-14 replacement region. An additional goal is to 
determine the capacity for in vitro transduction by Sst-RBS compared to WT and 
VSV G envelope proteins in an effort to develop a high capacity LV vector 
suitable for targeting in vivo gene delivery. 
 
• The objective of Chapter 4 is to identify characteristics of the cellular receptor 
that influence infection. By investigating how intracellular events following 
receptor endocytosis affect the outcome of infection I hope to assess if 
specifically targeting receptors with certain intracellular pathways should be 
considered in the development of future targeting vectors. 
 
• The objective of Chapter 5 is to demonstrate proof of principle for in vivo 
transduction and identify regions of the murine brain with endogenous surface 
expression of SSTRs that are susceptible to infection by the Sst-RBS 
glycoprotein.  
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 Chapter 2. Methods 
 
 
Cell Lines 
 
Cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) high glucose 
supplemented with 8% donor calf serum (Invitrogen) for mouse NIH 3T3 and HEK293 
(293) cells, or 8% fetal bovine serum (FBS, Invitrogen) plus 250 µg/ml G418 (BioGold) 
for the H1BAG, 293/SSTR-2, -3, -5 and 293FT cells.  
 
 
293/SSTR-expressing Cell Lines 
 
The 293/SSTR-5 cell line was generated using plasmid Alpha+12CA5/SSTR5 
(Affymax, Palo Alto, CA) and sorted as previously described to obtain a population 
expressing cell surface SSTR-5 at levels comparable to that of endogenous mCAT-1 on 
NIH 3T3 cells [25]. The 293/SSTR-2 and -3 cell populations were generated similarly by 
transfection of 293 cells with expression plasmids Alpha+12CA5/SSTR2 or 
Alpha+12CA5/SSTR3 (Affymax) encoding amino-terminal HA epitope tagged human 
SSTR subtypes 2 and 3, respectively, linked to a G418 resistance gene cassette, and 
stable transfectants selected by culture in 1 mg/ml G418 for four weeks followed by 
Fluorescence activated cell sorting (FACS) using mouse anti-HA monoclonal antibody 
HA.11 (Covance, 1:200 dilution) and goat anti-mouse conjugated to Alexa488 (Molecular 
Probes, 1:400 dilution) to obtain populations whose surface expression of SSTR-2 or -3 
was comparable to that of the 293/SSTR-5 cell line. 
 
 
HIBAG Producer Cell Line 
 
The H1BAG cells used to produce pseudotyped MLV particles has been described 
previously [25]. Briefly, HEK293 cells were transfected with the BAG genome [40] and 
single-cell cloned to obtain a population of cells stably expressing a murine leukemia 
virus intact long-terminal-repeat controlled lacZ-transducing retroviral genome. 
 
 
Plasmid Construction 
 
 
Sst-RBS and Flexible Flanking Sequence Modified Glycoproteins 
 
The following primer sequences were created to generate intermediate plasmids 
pcDNA-Sst-RBS and pcDNA-Sst-RBS-2 from pcDNA-DelRBS-Opti (a plasmid encoding 
a codon optimized version of the MLV env in which the RBS has been deleted) using 
ExSite Mutagenesis technology (Stratagene) and PrimeStar HS DNA Polymerase 
(Takara); DelRBS-Opti Return Primer: 5’ PHOS G TCC TGG AGG ACT ACT GAA TG 
3’, DelRBS-Opti SstMut1 Primer: 5’ PHOS CG CCT TAC GCG TCC GCT GGC TGC 
AAG AAT TTC TTC TGG AAG ACC TTC ACT AGT TGC GCG TAT ACC GCT AGT 
GAG GAG CCA CTG AC 3’, and DelRBS-Opti SstMut2 Primer: 5’ PHOS CT CCT AGC 
GGC GGT GGA GGA GCT GGC TGC AAG AAT TTC TTC TGG AAG ACC TTC ACT 
AGT TGC AGC GGT GGA GGA GGC GAG GAG CCA CTG ACA TCT TTG 3’. The 
unique restriction sites PmlI and BspEI in pcDNA-DelRBS-Opti and the SpeI site in 
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 Sst-RBS were used to recombine the 5’ and 3’ flanking sequences to generate two more 
plasmids; pcDNA-Sst-RBS-3 and pcDNA-Sst-RBS-4. The restriction sites PmlI and 
BspEI were again used to lift the four Sst-RBS sequences out of the pcDNA-DelRBS-
Opti intermediate backbone and insert them into the TS45 expression plasmid 
generating Sst-RBS, Sst-RBS-2, Sst-RBS-3 and Sst-RBS-4. 
 
 
FEGW 
 
The expression plasmid encoding an HIV-based self-inactivating (SIN) LV genome 
encoding green fluorescent protein (GFP) under control of the human elongation factor 
1-alpha (hEF1α) was created by removing the human Ubiquitin C promoter (hUBC) from 
FUGW (Addgene [41]) and replacing it with hEF1α from pEF1/Myc-His A (Invitrogen) 
using In-Fusion (Clontech, manufacturer’s instructions) between the PacI and BamHI 
restriction sites with the following primers. EF1a-FUGW For: TGA TTA TTG ACT AGG 
CTT TTG CAA AAA GCT TTG CAA AGA TGG ATA AAG TTT TAA ACA GAG AGG AAT 
CTT TGC AGC TAA TGG ACC TTC TAG GTC TTG AAA GGA GTG GG and Ef1a-
FUGW Rev: GGA ATT AGC TTG GTA CTA ATA CGA CTC ACT ATA GGG AGA CCC 
AAG CTG GCT AGG TAA GCT TGG TAC CGA GCT CGG ATC CAC TAG TCC AGT 
GTG GTG GAA TTC TGC AGA TAT CCA GCA CAG TGG CGG CCG CTC GAG TCT 
AGA GGG CCC TT. 
 
 
Pseudovirus Production 
 
MLV pseudovirions transducing β-galactosidase were produced by calcium 
phosphate co-precipitation transfection of H1BAG cells using plasmids encoding the 
Moloney MLV gag and pol genes (35 µg) and either the wild type (WT) Moloney or 
Sst-RBS env gene (18 µg) or a vesicular stomatitis virus (VSV) G protein cDNA (4 µg) in 
a T-75 flask. The precipitant was removed and fresh growth media added after 16 hours, 
supernatants collected 24 and 48 hours later, and cell debris removed by 0.45 µM 
syringe filter (Millipore). Viral supernatants were generally used fresh (no freeze-thaw), 
further concentrated as indicated in the experimental procedure or stored at -80 °C for 
later use. 
 
Sst-RBS coated lentiviral pseudovirions transducing enhanced GFP were produced 
by Lipofectamine 2000 (Invitrogen, manufacturer’s instructions) transfection of 293FT 
cells (Invitrogen) with plasmids FEGW (3.75 µg) pCMVd8.2dvpr (Addgene, 11 µg) 
encoding the gag, pol and rev genes from HIV-1 and the Sst-RBS env gene (8.4 µg) in a 
T-75 flask. The VSV G LV was produced by Lipofectamine 2000 transfection of 293FT 
cells with FEGW or FUGW (3.75 µg) and the Virapower Lentivirus plasmid mix 
(Invitrogen, 11.25 µg) in a T-75 flask. The transfection mix was removed and fresh 
growth media without phenol red added after 16 hours, supernatants collected 24 and 48 
hours later, and cell debris removed by 0.45 µM syringe filter. Supernatants were 
concentrated by ultracentrifugation at 18,000 rpm for 3 hours at 4 °C (Beckman Coulter 
Optima L-90K Ultracentrifuge SW28 rotor) then resuspended in ice cold phosphate 
buffered saline (PBS) at 100-fold the original volume. Concentrated lentiviral stocks were 
used fresh (no freeze-thaw) or stored at -80 °C for later use. 
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 Lentivirus transducing mKate2, firefly luciferase and puromycin resistance were 
produced by the University of Tennessee Health Science Center Viral Vector Core.  
 
 
Infection Assays 
 
End-point dilution titrations of MLV pseudovirions were performed by exposing host 
cells seeded (at approximately 25% confluence to allow room for cell division necessary 
for MLV provirus integration) in quadruplicate on 48-well plates to ten-fold serial dilutions 
of virus supernatant in the presence of 10 µg/ml polybrene (Sigma) using spinoculation 
(centrifugation at 2250 rpm in a Jouan CR 412 for 30 minutes at 24 °C). Forty-eight 
hours later, the cells were fixed with 0.5% gluteraldehyde, stained with 5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside (X-Gal) and transduction was quantified by 
scoring the lacZ positive foci using light microscopy.  
 
Titration of puromycin resistance-transducing lentiviral stocks was performed 
similarly except that 36 hours after virus exposure, cells were fed with medium 
containing 1 µg/ml puromycin and the drug was maintained for two weeks at which time 
surviving drug-resistance colonies were fixed and stained for enumeration using 1% v/v 
crystal violet (Sigma) in Ethanol. For GFP-transducing LVs, host cells were seeded (at 
approximately 40% confluence) in a 24-well plate and exposed to 300 µl of 100X 
concentrated lentiviral (100,000 NMWL Centricon-Plus Millipore) stock resuspended at 
5X for Sst-RBS or 1x10-2 for VSV G pseudotypes in the presence of 10 µg/ml polybrene. 
Cells were spinoculated, and split into 6-well dishes 16 hours later. Infection was 
quantified by flow cytometry for the presence of GFP at 72 hours post infection (hpi). 
 
 
SDS PAGE Western Blot Analysis 
 
Virus supernatants were prepared for analysis by concentrating 9 ml by ultra-
centrifugation at 30,000 rpm for 90 minutes at 4 ºC and resuspending the pellet in 30 µl 
of ice cold PBS. Pre-cast 4-20% Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS PAGE) gels (Pierce) were loaded with 10 µl pellet in 2X gel 
loading dye boiled at 95 ºC for 10 minutes or 5 µl protein marker (Bio-Rad). The gel was 
electrophoresed for 15 minutes at 80 V then 30 minutes at 110 V. Protein was 
transferred to a nitrocellulose membrane overnight at 30 V. The membrane was probed 
with goat anti-Rauscher SU (Quality Biotech, 1:100 dilution) a primary antibody 
recognizing the MLV SU protein for 1 hour, horseradish peroxidase conjugated 
secondary antibody for 1 hour (Sigma, 1:5,000 dilution) and visualized with 
chemiluminescent substrate (Pierce). The membrane was stripped (Bio-Rad) and re-
probed using goat anti-Rauscher CA (1:10,000 dilution) a primary antibody recognizing 
the MLV capsid protein as a loading control. 
 
 
Virus Binding 
 
Equilbrium binding assays were performed as previously described [42]. Briefly, 
Sst-RBS MLV was concentrated 20X by low speed centrifugation using Centricon-100 
devices (Millipore) then incubated with approximately 1x106 non-transfected 293 or 
293/SSTR-2, -3, or -5 cells for 30 minutes at 37 °C to allow maximal virus particle 
binding. After washing out unbound virus with PBS the cells were incubated for 1 hour at 
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 4 °C with goat anti-Rauscher SU (Quality Biotech, 1:100 dilution) cleared by 
pre-incubation with 293 cells and for 30 minutes with mouse anti-goat Alexa-488 
(Molecular Probes, 1:400 dilution). Finally, 2 µg of propidium iodide (Sigma) added to 
gate out membrane compromised cells. Flow cytometry of at least 10,000 events was 
performed and the population of propidium iodide -negative, Alexa-488-positive cells 
was analyzed. The fold binding of Sst-RBS MLV to each cell line was determined by 
comparing the mean fluorescent intensity (MFI) of each SSTR-expressing cell line 
exposed to Sst-RBS MLV to the MFI of non-exposed populations (this normalizes for 
background fluorescence).  
 
 
Receptor Internalization 
 
Receptor internalization studies were performed similarly to the equilibrium virus 
binding assay but with the following exceptions: incubation with 1 µM of synthetic 
SST-14 peptide (Sigma, S-9129) for 30 minutes followed by incubation for 1 hour at 4 °C 
with mouse anti-HA.11 monoclonal antibody (Covance, 1:200 dilution) and goat 
anti-mouse conjugated to Alexa488 (Molecular Probes, 1:400 dilution). 
 
 
Kinetics of Virus Internalization 
 
To determine the internalization kinetics viruses were spinoculated onto host cells 
seeded in quadruplicate wells of 48-well plates by centrifugation at 2250 rpm (Jouan CR 
412) for 30 minutes at 4 °C in the presence of 10 µg/ml polybrene, after which 
non-internalized virions were inactivated by a pH 3.0 citrate buffer wash immediately (0 
hour time point) or at various times after shifting the cells to 37 °C as previously 
described [43]. Infection was allowed to continue for 48 hours prior to fixation with 0.5% 
gluteraldehyde and stained with X-Gal. β-galactosidase activity was quantified using the 
Romanizer software package ((http://cfar.ucsd.edu/romanizer/) as described by Day and 
coworkers [44] except that the digital images of whole fixed and stained wells were 
captured using a D50 digital camera (Nikon) mounted on a SZ-PT microscope 
(Olympus) by Tim Higgins in the Department of Microbiology, Immunology and 
Biochemistry. In a pilot experiment, infected 293/SSTR-5 and NIH 3T3 cells were too 
numerous to count accurately either by visual scoring using light microscopy or using the 
Romanizer software so in the experiments reported here these cell lines were 
spinoculated with 100-fold dilutions of the Sst-RBS or WT MLV, while the 293 and 
293/SSTR-2 and -3 host cells were spinoculated with neat Sst-RBS MLV stocks. The 
relative rate of virus internalization was calculated by non-linear regression analysis 
using GraphPad Prism software and the amount of time to reach 50% infection 
extrapolated from each equation. 
 
 
Drug and Inhibitor Studies 
 
Stock solutions were prepared as follows: 500 mM methyl-β-cyclodextrin (Sigma, 
C4555), 30 mM chloroquine diphosphate salt (Sigma), 5 mg/ml leupeptin hemisulfate 
(Peptides International) in H2O, 3 mM monensin in EtOH (ready to use as GolgiStop, 
BD) and 10 mM CA074 Me (Peptides International), 10 mM nocodazole (Sigma), 20 mM 
bafilomycin A1 (Sigma) in DMSO. Cells seeded in quadruplicate wells on 96-well plates 
were pretreated with medium containing the indicated concentration of each compound 
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 or vehicle for 30 min (methyl-β-cyclodextrin; bafilomycin A1, chloroquine, monensin and 
CA074 Me) or 1 hour (leupeptin and nocodazole) at 37 °C, then virus was spinoculated 
as described above except that virus plus drug or vehicle was maintained for 3 hours 
after spinoculation, then unbound virus and drugs were removed by two gentle washes 
with culture medium. For cells treated with methyl-β-cyclodextrin, each well was rinsed 
twice with Optimem I serum-free medium and methyl-β-cyclodextrin or vehicle was also 
diluted in Optimem I prior to its addition to adherent cells. At 48 hpi, cells were fixed and 
stained with X-Gal and transduction was scored using the Romanizer software to 
analyze digital images of entire wells. In order to obtain levels of infection that could be 
accurately quantified, 1:20 dilutions of control VSV G MLV were used on all cell lines 
and the same dilutions of Sst-RBS and WT MLV on 293/SSTR-5 and NIH 3T3 cells, 
respectively. The amount of infection in the vehicle-only control wells was taken as 
100% infection and the percent infection of each cell line was calculated for each 
experiment individually to determine the mean percent infection in the quadruplicate 
wells. 
 
 
Quantitative Real-time PCR Analysis 
 
The quantitative real-time PCR assays were performed as previously described by 
Gao and colleagues [45] with the following modifications. New primer sets were 
developed for the MSS and lacZ of the recombinant MLV genome, and for human and 
murine β-actin control amplicons. Three-fold concentrated Sst-RBS or WT MLV 
pseudovirions, or mock (no virus) were spinoculated onto the cells by centrifugation at 
2250 rpm (Jouan CR 412) for 30 min at 4 °C in the presence of 10 µg/ml polybrene, then 
unbound virus was washed away and the cells fed fresh medium. Whole cell DNA was 
isolated immediately with no temperature shift for the zero time point, and replicate 
samples were also shifted to 37 °C for 6 hours prior to DNA isolation using a DNeasy 
Blood and Tissue Kit (Qiagen). The whole cell DNA was used directly as template for 
analysis by quantitative real-time PCR using the Light Cycler 480 instrument (Roche) 
and the following primer and probe sets: Minus Strand Strong Stop (MSS), forward 
(MSS82-F) 5’-ACT TGT GGT CTC GCT GTT CC-3’, reverse (MSS82-R) 5’-CGC TGA 
CGG GTA GTC AAT C-3’ and Universal Probe #82 (Roche); LacZ gene, forward 
(LacZ74-F) 5’-GAC CGC ATG GTC AGA AGC-3’, reverse (LacZ74-R) 5’-CTG AGG TTT 
TCC GCC AGA C-3’ and Universal Probe #74;  Human β-actin gene, forward (hBAct60-
F) 5’-GCC GTG TTC TTT GCA CTT TC-3’, reverse (hBAct60-R) 5’-GCA GAG ATG CAC 
CAT GTC AC-3’ and Universal Probe #60;  murine β-actin gene: forward (mBAct29-F) 
5’-CAC GCC CTT TCT CAA TTG TC-3’, reverse (mBAct29-R) 5’-CCA AGG GAG ACT 
CAG CTC ATA-3’ and Universal Probe #29. MSS and LacZ gene amplification were 
normalized to the values obtained for β-actin amplification for each respective host cell 
line. The relative amount of cell-associated virus was calculated by comparing the MSS 
amplification signal at the 6 hour time point for each SSTR-expressing cell lines to the 
level in the parent 293 cells using the delta delta Ct calculation. Values were then 
expressed as the relative fold increase over the 293 value. To determine the relative 
amount of penetrated virus the delta delta Ct calculation was used to calculate the 
relative level of MSS signal at the zero and 6 hour time points with respect to the level of 
LacZ gene signal in each cell line, and then expressed as the fold increase over the zero 
hour time point. 
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 In Vivo Experiments 
 
 
Animals 
 
The animal protocol used in this study has been approved by the Institutional Animal 
Care and Use Committee at the University of Tennessee Health Science Center 
(UTHSC). Nine to twelve week old C57BL/6J mice were purchased from Charles River 
Laboratories (Wilmington, MA, USA). Mice were allowed free access to food and water. 
 
 
Intracranial Microinjection 
 
Bilateral, stereotaxic microinjections were performed on anesthetized mice using 
the following protocol. Nine to twelve week old C57BL/6 mice skulls were shaved and 
incision site prepped with betadine then mice were mounted into a stereotaxic 
apparatus. Small holes were drilled in the skull bone directly above the injection sites 
and a 30-gauge Hamilton microsyringe lowered to the following coordinates from 
bregma: Caudate Putamen: AP= -0.5, ML= ±2.0, DV=-4.0; Subthalamic Nucleus: 
AP= -1.9, ML= ±1.5, DV= -5.2. After the microsyringe had been lowered to the 
coordinates, it was left in place for 10 minutes before and after administration of lentiviral 
injections. A total volume of 2 µl concentrated Sst-RBS or a 100-fold dilution of 
concentrated VSV G pseudotyped lentiviral vectors transducing a SIN HIV-1 based 
genome encoding the marker gene mKate2 under the hUbC promoter were injected into 
the left hemispheres of 4 mice at a rate of 0.7 µl/min. The same virus preparations were 
also injected into the contralateral hemisphere of each mouse immediately after injection 
with 0.5 µl of 100 µM SST-14 peptide. After the injection procedure was complete, the 
skull incision was closed and mice were allowed to recover in a BSL-2 housing facility. 
Three days post infection the mice were sacrificed, organs perfused with PBS and the 
brain tissue recovered for analysis. 
 
 
Tissue Section Staining 
 
Brain tissue from injected and control mice were fixed in 4% paraformaldehyde then 
sunk in a 25% sucrose phosphate buffer solution and flash frozen in Isopentane. A 
microtome was use to slice 20 µm sections which were placed on clean, glass slides. 
Slides were soaked in 1X PBS to remove the sucrose solution from the sections just 
prior to staining to allow antibodies proper access to epitopes. Sections were blocked for 
20 minutes with 3% BSA/ 0.8% Triton X-100/ 0.2M PBS prior to co-incubation with 
monoclonal rabbit anti-SSTR-2 (Epitomics, 1:1000 dilution) and monoclonal mouse 
anti-neuronal nuclear membrane protein (NeuN) (Millipore, 1:2000 dilution) diluted in 
blocking buffer overnight followed by incubation with Alexa-488, Alexa-594 or Alexa-647 
conjugated secondary antibodies (Molecular Probes, 1:1000 dilution) for 2 hours. 
Hoechst nuclear stain (100 µM) was added to stained sections for 20 minutes prior to 
mounting in 90% glycerol/PBS and imaged on a Zeiss Deconvolution microscope or in 
FluorSave (Calbiochem) and imaged using an Aperio Scanscope. 
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 Transduction Zone Measurements 
 
The mean transduction area (TA) of multiple sections from three mice injected with 
2 µl of either the Sst-RBS or VSV G pseudotyped LV vectors was quantified using 
ImageJ software (National Institutes of Health, v1.46r). Transduction of mKate2 was 
analyzed for each coronal section. These values were then used to calculate a mean TA 
for individual mice and an overall mean TA for each lentiviral vector. 
 
The mean transduction zone (TZ) of multiple sections from three mice injected with 
2 µl of either the Sst-RBS or VSV G pseudotyped LV vectors, in the presence or 
absence of 100 µM SST-14, was quantified by measuring the height (h) and width (w) of 
the core and maximum TZ using ImageScope software (Aperio, v11.2.0.780) and 
calculating the elliptical area using the formula a=πhw/4. The core TZ was defined as the 
area with the highest concentration of mKate2 expression and the maximum TZ as the 
largest overall area of mKate2 expression. Mean TZ areas were calculated for individual 
mice which were then used to calculate an overall mean TZ area for each lentiviral 
vector. 
 
 
Statistical Analysis 
 
 Descriptive statistics for all data were performed using Prism GraphPad Software 
v4.0. 
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 Chapter 3. Targeted Entry via Somatostatin Receptors Using a Novel Modified 
Retrovirus Glycoprotein that Delivers Genes at Levels Comparable to Those of 
Wild-Type Viral Glycoproteins† 
 
 
Introduction 
 
Retro- and lentivirus vectors are commonly used as vehicles for marker and 
therapeutic gene delivery because they naturally integrate a copy of their genomic 
material into the host chromosome during infection. Generally, these vectors use the 
Env glycoprotein from amphotropic MLV or the VSV G protein. Unfortunately, the broad 
tropism of these glycoproteins mediates gene transduction of most cells after in vivo 
injection, resulting in the need for a far greater vector inoculum than would be required if 
entry could be restricted to the target cells or tissues capable of benefiting from 
therapeutic gene delivery. This is one of the most significant challenges to targeted in 
vivo gene delivery [13].  
 
Addressing the need for targeted delivery in vivo, a number of approaches based on 
RV and LV particles have been reported (for reviews see [11, 12]). Placing glycoproteins 
modified with ligand insertions directed to cellular receptors onto virus particles 
(pseudotyping) is a common strategy. Although these chimeric virions were generally 
able to bind their receptors and internalize, membrane fusion was impaired resulting 
very low levels of transduction [13-15]. Since Env conformational changes are normally 
activated by interactions of the Env RBS with its cellular receptor to initiate membrane 
fusion, a new strategy was proposed to replace the MLV RBS with a peptide ligand.  
 
Other researchers in this laboratory demonstrated that a chimeric MLV Env 
glycoprotein based on this design, Sst-RBS (Figure 1-1), was capable of infecting 293 
cells expressing the SSTR-2 receptor and no longer used its natural receptor, mCAT-1. 
This infection was found to be SSTR-specific as evidenced by dose-dependent inhibition 
of infection using exogenous SST-14 peptide [25]. The strategy used in designing the 
Sst-RBS glycoprotein should mimic natural virus-receptor interactions as the Sst-RBS 
Env binds to its target receptor and be capable of inducing membrane fusion, thus 
allowing targeted transduction. It was demonstrated that an important positional 
requirement for the glycoprotein was satisfied by placing the SST-14 sequence at the 
RBS. In this chapter I report that an additional glycoprotein characteristic, conferred by 
specific structural properties of the Sst-RBS replacement sequence, influences infection. 
Additionally, the transduction capacity of pseudovirions bearing the Sst-RBS 
glycoprotein was comparable to the efficiency of natural retroviral glycoproteins and 
approached that of VSV G; establishing Sst-RBS as a suitable candidate for in vivo gene 
transfer. 
 
 
 
 
† Adapted with permission.  Li, F., B. Y. Ryu, R. L. Krueger, S. A. Heldt and L. M. 
Albritton.Targeted entry via somatostatin receptors using a novel modified retrovirus 
glycoprotein that delivers genes at levels comparable to those of wild-type viral 
glycoproteins. J Virol, 2012. 86(1): 373-381. 
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 Results 
 
 
Sst-RBS Is Capable of Transducing 293/SSTR-5 Cells at Levels Comparable to 
Wild-type Transduction of NIH 3T3 Cells 
 
To begin investigating Sst-RBS transduction capacity, I compared its transduction 
with WT and VSV G pseudotyped MLV particles by end-point dilution titration (Figure 
3-1A). In four independent titrations, the mean LacZ transducing units per ml of Sst-RBS 
reached 5.6 x 105 (range of 2.5 x 105-1.0 x 106) in SSTR-5 expressing cells, WT reached 
5.8 x 105 (range of 2.5 x 105-1.0 x 106) in NIH 3T3 cells expressing the natural receptor 
and VSV G reached 1.1 x 106 (range of 1.0 x 105-2.5 x 106) in 293 cells (Figure 3-1B). 
 
 
Pseudovirion Binding to SSTR-5 Is Comparable to mCAT-1 
 
When comparing the level of infection of the Sst-RBS glycoprotein to that of WT, it is 
important to maintain comparable numbers of available binding sites on each of the cell 
lines. To do this, a binding assay was performed with both pseudovirions. This assay is 
described in detail in the virus binding assay section of Chapter 2. Briefly, 293/SSTR-5 
cells and NIH 3T3 cells were incubated with the appropriate virus and levels of 
attachment were quantified by flow cytometry using antiserum to the MLV SU Env 
(Figure 3-2A). The mean fluorescent intensity (MFI) of the bound virus can be used as a 
measure of the relative number of pseudovirion binding sites since the anti-SU 
antiserum appeared to recognize the Sst-RBS and WT Env similarly in immunoblots 
[25]. In three independent assays, Sst-RBS MLV showed a mean increase of 2.9 ± 0.7-
fold in binding to SSTR-5 expressing cells over cells incubated with antibody alone and 
WT MLV showed a mean increase of 4.3 ± 0.2-fold. Histograms from a representative 
assay are shown in Figure 3-2B. Because these receptors are multi-membrane 
spanning proteins virus binding kinetics cannot be accurately determined; however, the 
difference in the level of virus binding to these cells indicates that the binding of WT to 
the murine cell line NIH 3T3 is only slightly greater than the capacity for Sst-RBS binding 
to SSTR-5 expressing cell. Thus, the effective number of receptor binding sites can also 
be considered comparable assuming that the receptors display similar off-rates. 
 
 
A Non-flexible Turn Flanking the SST-14 Ligand Insertion Is Required for Sst-RBS 
Infectivity 
 
A primary reason for the failure of many Env retargeting designs can be attributed to 
improper structural relationships and protein folding. Incorrectly folded glycoproteins 
might not be incorporated into the viral membrane or fail to complete membrane fusion 
because critical conformational changes are impeded [11, 46]. Replacing the natural 
RBS minimizes this concern by leaving critical residues in the amino-terminus free [8], 
however steric hindrances may still exist that prevent efficient transduction. As such, it 
has been shown that the addition of flexible peptides might alleviate these constraints 
[14, 47]. 
 
To determine if structural requirements of the Sst-RBS glycoprotein have an effect 
on transduction capacity, mutagenic PCR techniques were used to alter the Sst-RBS 
insertion sequence by replacing the amino- or carboxy-flanking sides of the SST-14  
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Figure 3-1. Sst-RBS glycoprotein targets entry at levels comparable to those of 
entry mediated by wild-type Moloney murine leukemia virus glycoprotein and 
approaching those of VSV G pseudovirions 
 
A. Experimental time line for transduction assays. 
 
B. NIH 3T3, 293, or 293/SSTR-5 cells were exposed to 10-fold serial dilutions of 
independently produced MLV vectors pseudotyped with the Sst-RBS (left) WT (middle) 
or VSV G (right) envelope glycoprotein and the titers were calculated from the endpoint 
dilutions. Data represent the mean ± SD of 3-4 independent titrations (n=4). 
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Figure 3-2. Generation of a host cell line stably expressing levels of target 
receptor SSTR comparable to the levels of ecotropic receptor on NIH 3T3 cells 
 
A. Experimental time line for virus binding assay. 
 
B. 293 cells were transfected with a cDNA-encoding human SSTR-5 with an amino-
terminal HA epitope tag, selected for G418 resistance and further selected for surface 
expression of the target receptor by three rounds of FACS using anti-HA antibody, 
yielding a population of cells designated 293/SSTR-5 .The 293/SSTR-5 (left) or NIH 3T3 
(right) cells were incubated with Sst-RBS or WT pseudovirions or mock incubated (No 
virus), and then both samples were incubated with goat anti-SU antiserum followed by a 
mouse anti-goat Alexa488-conjugated secondary antibody plus propidium iodide at the 
temperatures indicated in the experimental time and analyzed by flow cytometry. The 
histograms shown are representative of the results of three independent binding 
experiments. Values shown represent the mean fold increase in Alexa488 intensities 
determined with live (propidium iodide-negative) cells.  
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 ligand with the flexible residues SGG or SGGGG, respectively (Figure 3-3). End-point 
dilutions were performed using pseudovirions coated with these glycoproteins. The 
mean titers of three independent titrations of the flexible linker-modified viruses obtained 
from 293/SSTR-5 cells are presented in Figure 3-4A. Modifying the flanking sequences 
of Sst-RBS did not improve infection and, in fact, placing a flexible sequence before the 
SST-14 ligand had a deleterious effect. Only the level of infection of Sst-RBS-3 was 
comparable to the original Sst-RBS construct and levels of WT infection on NIH 3T3 
cells. Infection of Sst-RBS-2 and Sst-RBS-4 were both decreased. 
 
SDS-PAGE western blot analysis was performed on concentrated pellets obtained 
from supernatants of WT, Sst-RBS and Sst-RBS-2 through 4 and probed with anti-SU 
antiserum. The MLV capsid (CA) protein served as a loading control since each virus 
particle contains approximately the same amount of this protein. The SU and CA band 
intensities were quantitated and the intensity of each SU band was normalized to the 
amount of respective CA (Figure 3-4B). Sst-RBS displayed a band intensity that was 
only slightly lower than the intensity of the WT band. In contrast, Sst-RBS-2, -3 and -4 
had reduced band intensities indicating that the modifications to these glycoproteins 
caused decreases in their incorporation into the viral membrane possibly because the 
glycoproteins were unable to fold into the correct conformation. 
 
 
Sst-RBS Pseudotyped Lentiviral Vectors 
 
To further characterize the usefulness of Sst-RBS, HIV-based SIN lentiviral vectors 
transducing the far-red fluorescent protein mKate2 and firefly luciferase were 
pseudotyped with Sst-RBS (Sst-RBS LV) or VSV G (VSV G LV), concentrated and 
certified replication incompetent by the UTHSC Viral Vector Core. Transducing units 
(TU/ml) of these vectors were quantified by end-point dilution titration on 293/SSTR-5 
and 293 cells using a standard luciferase assay by the vector core. The VSV G LV stock 
 
 
 
 
Figure 3-3. Modified Sst-RBS glycoproteins containing the SST-14 ligand 
 
 text indicates linker sequences, italic text indicates disulfide bonded cysteine BOLD
residues, underlined text indicates SST-14 replacement sequence, and 
highlighted text indicates residues required for receptor binding. 
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Figure 3-4. Glycoproteins with a non-flexible peptide linker sequence upstream 
of the SST-14 ligand retain infectivity 
 
A. Ten-fold dilutions of MLV virions coated with Sst-RBS, the flexible-linker modified Sst-
RBS-2, -3, and -4 (purple) or WT (black) glycoproteins were exposed to 293/SSTR-5 or 
NIH 3T3 cells and infection scored by LacZ transduction (unpublished data). The 
presence or absence of amino- and carboxy-flanking flexible residues is indicated under 
the bars corresponding to each pseudovirus. Data represent the mean ± SD of 3 
independent titrations (n=4). 
 
B. SDS PAGE Western Blot was performed on concentrated virus pellets from a 
representative production of the pseudovirions in (A) (unpublished data). The membrane 
was probed with goat-anti p70/SU recognizing the MLV glycoprotein, stripped and re-
probed with goat-anti p30/CA recognizing the MLV capsid protein as an indication of the 
overall virus particles present in each sample.  
19 
 contained 2.3 x 109 luciferase TU/ml and the Sst-RBS LV stock contained 9.2 x 106 
luciferase TU/ml. This represents an approximate 200-fold difference in titer between 
VSV G and Sst-RBS LV. This is similar to titers of other retroviral glycoprotein 
pseudotypes of lentiviral vectors and is thought to result from lower assembly of other 
glycoproteins compared to VSV G due to their cytoplasmic tail sequences [23, 48, 49]. 
Sst-RBS and VSV G LV particles transducing GFP under the control of the hUbC 
promoter (Figure 3-5A) were produced in an effort to detect transduction by flow 
cytometry analysis. In accordance with the difference in luciferase TU/ml, the MFI of 
VSV G LV transduced 293/SSTR-5 cells was detected well above the background MFI 
of mock exposed cells while Sst-RBS LV transduction could not be detected. When the 
promoter element of this HIV-based genomic construct was replaced with the hEF1α 
promoter, the MFI of both constructs increased so that Sst-RBS transduction of SSTR-5 
expressing cells was detectable; however, VSV G transduction was 20.2-fold higher 
(Figure 3-5B).   
 
 
Discussion 
 
Many RV and LV receptors are multiple membrane spanning proteins such as the 
chemokine co-receptors used by HIV [50], Xpr1 used by xenotropic MLV [51] and 
mCAT-1, the natural Moloney MLV receptor [52]. Although SSTR are not entry receptors 
for any known virus they also have multiple membrane spanning domains. Conversely, 
the epidermal growth factor (EGF) receptor (ErbB) has a single transmembrane domain. 
Chimeric virions containing an insertion of EGF in amphotropic [53] or Moloney [54] MLV 
Envs were capable of binding ErbB but no transduction was seen. These observations 
lead both Cosset and Katane’s groups to propose that receptor characteristics are the 
main consideration for developing an entry targeted viral vector, possibly because 
receptors that span the cellular membrane multiple times would bring bound virus into 
close contact with the cell [54]. Additionally, polytopic receptors such as these are often 
localized in cholesterol-rich lipid rafts which are crucial for the endocytosis and entry of 
many of enveloped viruses [55]. 
 
Research conducted while characterizing the Sst-RBS glycoprotein demonstrates 
that properties of the targeting glycoprotein are also an important parameter. Viral 
glycoproteins naturally assemble onto virions in a metastable conformation that is not 
competent for membrane fusion. In the case of gammaretroviral Env, the transition from 
a metastable to a fusion competent conformation is induced after receptor binding and 
begins with cleavage by host cell cathepsin proteases in the late endosomal 
compartment which subsequently triggers isomerization of the disulfide bond between 
SU and TM domains of Env [56]. These conformational changes expose the TM fusion 
peptide that is responsible for completing the membrane fusion process [57]. It follows 
that the Env sequences that bind natural retrovirus receptors possess the ability to 
initiate and sustain these critical conformation changes. This capacity most likely derives 
from the position of the RBS at the top of the receptor binding domain, and while this 
location may not be the only one with the capacity to initiate and sustain membrane 
fusion, it is the most effective one discovered to date [25]. Furthermore, the low level of 
LacZ transduction observed with Sst-RBS-2 and -4 coated viruses correlated with low 
levels of anti-SU probe signal in a western blot analysis (Figure 3-4), indicating that 
placing flexible sequences in this important region affected glycoprotein incorporation 
into the virion envelope. It is interesting that Sst-RBS-3 displayed a similar SU band 
intensity as Sst-RBS-2 and -4 but retained the same level of transduction as the original 
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Figure 3-5. Lentivirus transducing an EF1α-GFP transgene exhibits higher 
expression 
 
A. Schematic representation of the HIV-1 based SIN-lentiviral expression genomes. Both 
plasmids contain a CMV enhancer element substituted for the U3 region of the 5’ LTR 
and a deleted 3’ U3 region rendering the 5’ LTR of the integrated provirus inactive. 
FUGW (top) transduces a GFP reporter sequence under the human Ubiquitin C 
promoter (hUbC) and FEGW (bottom) transduces GFP under the human Elongation 
Factor 1-alpha promoter (hEF1α). R, repeat region; U5, unique 5’ untranslated region; 
HIV-1 FLAP, enhances titer by increasing cDNA nuclear import; EGFP, enhanced green 
fluorescent protein; WRE, woodchuck hepatitis posttranscriptional regulatory element; 
∆U3, unique 3’ untranslated region deletion. 
 
B. 293/SSTR-5 cells were exposed to mock (white bars) or unconcentrated VSV G (left 
panel) or Sst-RBS (right panel) coated lentiviral vectors transducing either FUGW (light 
bars) or FEGW (dark bars) and assayed by flow cytometry analysis 72 hours post 
infection for GFP fluorescence at the times indicated in the experimental timeline.  
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 Sst-RBS glycoprotein. Sst-RBS also exhibited a decrease in SU band intensity 
compared to WT which did not significantly affect its relative level of transduction. This 
suggests that the rigid structure provided by the original Sst-RBS insertion sequence 
may be a necessary structural element and it is this property, not the overall level of 
glycoprotein incorporation, which influenced the levels of transduction.   
 
These data strongly indicate that the chimeric Sst-RBS Env retains the structural 
characteristics that are necessary to initiate infection. Despite slightly lower levels of cell 
surface binding sites (Figure 3-2) and Sst-RBS Env detection by WB analysis (Figure 
3-4) and compared to WT, the Sst-RBS glycoprotein was capable of specifically 
delivering genes to cells expressing the SSTR-5 receptor with a transduction efficiency 
comparable to WT virus and approaching that of the “gold-standard” VSV G protein 
(Figure 3-1) demonstrating that the capacity of Sst-RBS MLV was within the range of a 
typical transduction vector. However, the difference in the level of transduction using an 
HIV-based LV vector pseudotyped with Sst-RBS or VSV G was larger than the 
difference seen from MLV particles pseudotyped with these Envs (Figure 3-5). The 
ability to transduce non-dividing cells is a distinct advantage of using LV vectors in in 
vivo systems. The influence of the 100-fold lower relative transduction capacity of Sst-
RBS LV compared to Sst-RBS coated MLV-based vectors as measured in cultured host 
cells would likely be outweighed by the mitotic requirement for MLV integration. There is 
a need for an in vivo targeting vector that is capable of directing high capacity 
transduction to particular cell or tissue types of interest. This chapter demonstrated that, 
in addition to the position of the targeting ligand, the structure of Sst-RBS glycoprotein 
allowed a high level of transduction. Hence, the Sst-RBS glycoprotein is a suitable 
candidate for mediating in vivo targeted transduction.  
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 Chapter 4. Characteristics of the Cellular Receptor Influence the Intracellular Fate 
and Efficiency of Retrovirus Infection ‡ 
 
 
Introduction 
 
Viral glycoproteins and their host cell entry receptors are thought to have co-evolved 
[58]. Data presented in Chapter 3 and published previously [25] highlighted the 
importance of glycoprotein characteristics on the efficiency of Sst-RBS-mediated 
transduction. While specific traits of the viral glycoproteins likely represented a major 
selective pressure driving the choice of receptor during that co-evolution [59], 
characteristics of candidate host cell receptors are also suspected of being involved but 
their possible influence has been difficult to assess [16, 60]. Virus-receptor complexes 
are internalized by existing endocytic mechanisms such as classical clathrin-mediated, 
caveolar/lipid raft associated, macropinocytosis, and phagocytosis [55, 61]. After 
budding from the plasma membrane, vesicles formed by these endocytic mechanisms 
become early endosomes (EE). As EEs mature into late endosomes (LE), the pH of their 
intralumenal environment decreases from physiological pH to as low as 5.0. Maturation 
is a dynamic process in which endocytosed cargo is sorted, numerous intralumenal 
vesicles are formed and various types of recycling vesicles bud off under the direction of 
numerous Rab GTPases and their associated effector molecules. During this process, 
the contents of endosomes are acted on by multiple cellular proteases that become 
activated as the pH decreases. LEs eventually fuse with lysosomes where the pH drops 
even further sustaining a highly acidic and proteolytically degradative environment [62]. 
Several pieces of circumstantial evidence suggest that the fate of internalized virus-
receptor complexes can strongly influence infection outcomes and thereby could have 
exerted selective pressure on the choice of a cellular receptor during evolution of viral 
glycoproteins. First, the Ebola virus fusion receptor (Neimann-Pick C1, NPC1) and 
activating host cell protease (cathepsin B) reside in a specific intracellular compartment 
[63, 64], suggesting that only filoviruses internalized into that compartment undergo 
efficient, productive entry. Second, inhibiting lysosomal degradation using 
pharmacologic agents increased infection by HIV-1 and the betaretrovirus enzootic nasal 
tumor virus (ENTV) [65-67], suggesting that internalization into degradative 
compartments can negatively impact the efficiency of entry. Third, specific inhibition of 
host cell cathepsin B increased infection of VSV G pseudotyped MLV [7] further 
suggesting that certain degradative compartments can be less productive destinations 
for entry. Lastly, prolonged neutralization of intracellular compartments decreased 
infection of the alpharetrovirus avian sarcoma and leukosis virus subgroup A (ASLV-A) 
[68] and re-routed virus-receptor complexes to different compartments [69], suggesting 
that the alternative compartments were less permissive than the compartment to which 
the virus normally traffics. 
 
The studies reported in this chapter took advantage of the unique opportunity 
provided by the Sst-RBS modified Env and its capacity to transduce cells by multiple 
cellular receptors to directly interrogate the influence of intracellular trafficking of 
internalized virus-receptor complexes on infection; asking if this characteristic of an entry 
‡ Adapted with permission. Krueger, R.L. and L. M. Albritton. Characteristics of the 
cellular receptor influence the intracellular fate and efficiency of retrovirus infection. J 
Virol, 2013. 87(10): p5916-5925.  
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 receptor influences infection. Subtypes SSTR-2, -3 and -5 were selected for this study 
because they are similar structurally and pharmacologically (e.g., kinetics of agonist 
binding and internalization) but have documented differences in intracellular trafficking 
that result in distinct intracellular fates after internalization (reviewed in [34]). SSTR-1 
and -4 were not included because they are not as efficiently internalized as the other 
subtypes after agonist exposure [30]. I quantified Sst-RBS pseudovirion infection on host 
293 cell lines stably expressing cell surface SSTR-2, -3 and -5 at levels comparable to 
each other, and to endogenous mCAT-1 expression on murine NIH 3T3 cells. This new 
model system circumvents the major technical constraints that have limited previous 
studies because the types of endocytic pathways and vesicular trafficking proteins 
available during infection are equivalent due to their 293 background. Additionally, the 
density of receptors and capacity for virus internalization are also comparable amongst 
the cell lines which were exposed to the same pseudovirus. Thus, differences in 
intracellular trafficking of internalized virus-receptor complexes should constitute the 
predominant influence on infection. Transduction assays revealed that Sst-RBS MLV 
and LV pseudotype transduction of the SSTR-2 and -3 cell lines was substantially lower 
than in the SSTR-5 expressing cells. Taken together the results of virus binding, 
internalization rate, lysosomatropic agent, protease inhibitor and penetration assays 
using quantitative real-time PCR support that infection via SSTR-5 is greater because 
viruses internalized by this subtype are directed to more permissive intracellular 
compartments, specifically to ones that are more favorable to penetration of the viral 
nucleocapsid than those compartments to which viruses bound to subtypes 2 and 3 are 
directed. These studies suggest that receptor characteristics such as intracellular 
trafficking exert a strong influence on the efficiency of infection and may have provided a 
selective pressure during retrovirus evolution guiding the choice of a host cell receptor. 
 
 
Results 
 
 
Infection of Sst-RBS Pseudotyped Viruses Is Greatest via SSTR-5 
 
Chapter 3 described the generation and characterization of a population of 293 cells 
stably expressing cell surface SSTR-5 at levels comparable to the relative number of 
endogenous ecotropic receptors (mCAT-1) on murine NIH 3T3 cells (Figure 3-2). For 
these studies, two additional stable cell lines were sorted for levels of SSTR-2 and -3 
comparable to that of the previously established 293/SSTR-5 cells (Figure 4-1) using an 
HA epitope tag present on each receptor subtype’s extracellular amino-terminus. Fusion 
of the HA tag sequence in this position does not alter agonist binding or internalization 
[35]. These matched cell populations were exposed to equal volumes of serially diluted 
Sst-RBS, WT MLV or VSV G MLV and the level of LacZ transduction assessed by end 
point dilution titration. Surprisingly, transduction was 222-fold and 23-fold lower in 
293/SSTR-2 and -3 cells, respectively, compared to the 293/SSTR-5 cells (Figure 
4-2A). Infection of control VSV G MLV and LV pseudovirions was comparable in each of 
the cell types indicating that the observed infectivity differences were Sst-RBS- and 
receptor subtype-dependent and thus not due to unspecific differences between the cell 
lines. There was no observable infection of the parent 293 cells. The SST-14 ligand is 
capable of binding endogenous murine somatostatin receptors [27] and a low level of 
infection (7.5 ± 1.4 TU/ml) was observed in NIH 3T3 cells exposed to Sst-RBS MLV. 
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Figure 4-1. SSTR-expressing cell populations display comparable levels of target 
receptors on their cell surface 
 
The steady state level of each SSTR subtype was quantified by flow cytometry using 
monoclonal antibody to the HA epitope tag located on the extracellular, amino-terminus 
of each receptor subtype. Representative histograms (purple, 293 cells expressing 
SSTR subtypes; black, background binding of the antibody to control 293 cells) are 
shown with values indicating the fold increase in mean fluorescent intensity over control 
293 cells.  
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Figure 4-2. Infection of pseudotyped viruses is greatest via SSTR-5 
 
A. 293 cells or the receptor matched 293/SSTR-2, -3, or -5 populations were exposed to 
ten-fold serial dilutions of Sst-RBS (purple bars), VSV G (white bars) or WT (black bars) 
pseudotyped MLV, spinoculated and incubated at 37 °C overnight. The level of infection 
was determined after 48 hours by scoring LacZ positive cells under a light microscope. 
 
B. Sst-RBS [5X] or VSV G (10-2) pseudotyped LV was exposed to each of the indicated 
cell types, spinoculated and incubated at 37 °C overnight. The level of infection was 
determined after 72 hours by flow cytometry analysis of GFP positive cells. 
 
Values represent the mean ± SD of 3 independent titrations (n=4). P-values were 
calculated by one way ANOVA and Bonferroni posttest. *, p ≤ 0.05; **, p ≤ 0.01.  
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 The trend observed with the MLV pseudovirions was also observed in five 
independent lentivirus infection assays using two pseudovirion stocks. Sst-RBS and 
VSV G LV particles transducing GFP were produced and the infectivity in 293, 
293/SSTR-2, -3, and -5 cells was analyzed by flow cytometry at 72 hpi. Sst-RBS 
mediated transduction was greater in SSTR-5 expressing cells with a mean of 0.9 ± 0.5 
percent of cells expressing green fluorescence above the background levels in 293 cells 
(Figure 4-2B). In each of the three experiments a few GFP positive foci were observed 
in the 293/SSTR-2 and -3 populations and no GFP expression was observed in 293 cells 
by visual inspection using fluorescent microscopy prior to detachment for flow cytometry. 
However, the difference between the actual MFI of the SSTR-2 and -3 cells (8.4 x 102 
and 7.4 x 102, respectively) and the background MFI of the 293 cells (6.2 x 102) was not 
statistically significant indicating that the low level of infection seen by visual inspection 
was below the level of detection by flow cytometry, evidently because the transduced 
cells represented an extremely low percentage of total cells. In two additional 
experiments, end-point dilution titration of LV transducing a puromycin resistance gene 
supported the flow cytometry results. Sst-RBS LV titers averaged 1 x 104 TU/ml in 
293/SSTR-5 cells and zero in 293/SSTR-2 and -3 cells (no puromycin resistant colonies 
observed). VSV G LV displayed titers of greater than 1 x 105 TU/ml in all cell lines. The 
lower infection of Sst-RBS LV compared to VSV G pseudotypes was consistent with 
previous results; when pseudotyped on MLV, the entry capacity of Sst-RBS showed a 
mean of 2.7 which ranged up to 5-fold of VSV G (Figure 3-1) but was 200-fold less 
effective on LV pseudovirions as measured by luciferase transduction. In accordance 
with the GFP transduction results, a p24 ELISA of a parallel production of Sst-RBS and 
VSV G LV pseudovirions used in the flow cytometry analysis revealed a 2.3 fold 
difference in the number of physical particles (data not shown). 
 
 
Receptor Specific Interactions Mediate Sst-RBS MLV Infection 
 
Sst-RBS MLV infection of SSTR-2 expressing cells was previously shown to be 
specific to this subtype as judged by dose-dependent inhibition by exogenous SST-14 
peptide [25]. To confirm that receptor specificity is retained by SSTR-3 and -5, end-point 
dilution titration was performed in the presence and absence of 1 µM of the SST-14 
peptide (Figure 4-3A). Sst-RBS MLV was competitively inhibited in each of the SSTR-
expressing cells by more than 80% (Figure 4-3B). Infection of NIH 3T3 cells by WT MLV 
or the SSTR expressing cells by VSV G MLV was unaffected by the presence of SST-14 
(Figure 4-3C).The downstream effects of ligand-somatostatin receptor binding, signal 
transduction events and receptor desensitization are complex and can vary depending 
on the ligand and cell type [29, 30, 34, 36]. One important potential outcome involves the 
initiation of anti-proliferative signals within the cell [29] which is especially relevant to the 
life cycle of MLV because proviral integration into the host chromosome is highly 
dependent on the mitotic stage of cell division [9]. To determine if SSTR engagement 
affects the cell’s ability to divide, the number of cells in each VSV G MLV positive foci (a 
cluster of β-galactosidase positive cells resulting from the division of one infected cell) 
was enumerated in the SST-14 treated and untreated populations from Figure 4-3C. If 
anti-proliferative signals are initiated through the SSTRs then the number of cells in each 
positive foci will be less in the SST-14 treated population than in the untreated cells. 
However, the mean number of cell divisions did not vary significantly among any of the 
SSTR cell types (Figure 4-4) indicating that the observed inhibition of infection via 
SSTR-2 and-3 was not due to a reduction in host cell division. 
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Figure 4-3. Receptor-specific interactions mediate Sst-RBS MLV infection 
 
A. Experimental time line for transduction in the presence of SST-14 inhibitor. 
 
B. Sst-RBS MLV infection was inhibited by preabsorption of cells with the SSTR agonist, 
SST-14. 293, 293/SSTR-2, -3, and -5 cells were incubated with 1 µM SST-14 peptide or 
mock-treated for 30 minutes prior to spinoculation of Sst-RBS MLV (purple bars) in the 
presence of 1 µM SST-14 or mock treated. Values show the mean relative infection ± 
SD in the presence of the peptide, calculated as (infection in the presence of SST-14 / 
infection in its absence) x 100. 
 
C. The peptide agonist did not affect infection of control pseudovirions. Cells were 
treated as in (A) except that infection was performed with VSV G (white bars) or WT 
(black bars) MLV pseudovirion stocks. 
 
All values represent the mean ± SD of three independent experiments (n=4). P values 
were calculated using two way ANOVA and Bonferroni post test. *, p ≤ 0.05; **, p ≤ 0.01.  
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Figure 4-4. The SST-14 ligand does not act by inhibiting cell division 
 
The mean number of cell divisions was determined by counting the number of cells in 
each β-galactosidase-positive foci from the VSV G MLV data in Figure 4-3B.  
 
All values represent the mean ± SD of three independent experiments (n=4). P values 
were calculated using two way ANOVA and Bonferroni posttest. *, p ≤ 0.05; **, p ≤ 0.01. 
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 The Relative Level of Cell-associated Virus Can Not Account for Differences in 
Transduction  
 
Although SSTR-2, -3 and -5 reportedly bind SST-14 with similar affinity [29], binding 
affinities between these somatostatin receptors and other ligands vary. For instance, 
while SSTR-2 and SSTR-3 bind the SST-28 precursor with comparable affinity to 
SST-14, SSTR-5 has a higher affinity for SST-28 [27, 30]. Furthermore, Octreotide, a 
synthetic peptide that mimics the agonist effects of the natural SST ligand, binds 
SSTR-2 with a higher affinity than both SSTR-3 and SSTR-5 [27, 34]. If binding to 
SSTR-2 and -3 is compromised by placing SST-14 in the larger context of the MLV Env, 
then increased infection of 293/SSTR-5 cells would be expected as the result of greater 
pseudovirion attachment. To investigate this possibility, equilibrium virus binding assays 
were performed as previously described [42, 70]. Briefly, each of the SSTR-expressing 
cell lines were incubated with Sst-RBS MLV pseudovirions and the relative levels of 
attachment were quantified by flow cytometry using anti-SU antiserum. In three 
independent assays, Sst-RBS MLV showed a mean increase of 2.89 ± 0.7-fold in 
binding to 293/SSTR-5 over cells incubated with antibodies alone; an increase that was 
not significantly different from the mean for SSTR-2 and -3 cells (2.27 ± 0.6 and 
2.54 ± 0.3-fold, respectively). The histograms from a representative assay are shown in 
Figure 4-5A. However, Sst-RBS binding to 293 cells was also similar indicating that a 
majority of detectable virus binding can be attributed to a cellular factor common to 293 
cells. An additional limitation of these results is that virus-receptor complexes 
internalized during the 37 °C binding step would not be accounted for in this 
quantification of surface pseudovirions. Additional experiments in which the binding step 
was carried out at 4 °C to inhibit virus-receptor complex internalization yielded only 
background levels of Sst-RBS and WT MLV binding (data not shown), findings 
consistent with previous reports that MLV binding at lower temperatures is limited [70, 
71].  
 
To address the extent of virus-receptor complex internalization and control for virus 
associated with the SSTR-expressing cell lines due to their 293 cell parentage, a 
quantitative real-time PCR assay was designed to take advantage of the unique 
characteristic of many retroviruses, including MLV, wherein reverse transcription of 
genomic RNA (gRNA) has been primed and the Minus Strand Strong Stop (MSS) cDNA 
generated and packaged into mature virions along with the gRNA [72]. Using a primer 
set designed to specifically amplify the MSS species (Figure 4-5B); the relative level of 
receptor-associated virus particles (i.e. the amount of virus both internalized and bound 
at the cell surface) was measured as a more precise quantification of total virus. 
Internalization of virus was synchronized in each of the SSTR-expressing cell lines by 
spinoculation at 4 °C prior to shifting cells to 37 °C. At six hpi the amount of MSS cDNA 
was quantified by quantitative real-time PCR. There were no statistically significant 
differences in the fold increase of virus associated with each of the SSTR subtypes 
(Figure 4-5C). The amount of virus associated with each of the SSTR-expressing cell 
lines was also comparable at zero hpi (no 37 °C shift) with mean relative fold increases 
of 1.1, 1.1 and 0.86 while the mean increases after 6 hours were 0.93, 1.3, and 0.99 for 
SSTR-2, SSTR-3 and SSTR-5; respectively. The difference between the amounts of cell 
associated virus at zero and 6 hpi in each cell line was not significantly different 
indicating that the MSS signal was not amplified during the 6 hour incubation and that 
the MSS cDNA was synthesized in the mature virion prior to the start of the experiment. 
Together these experiments indicated that there are no differences in virus binding or,  
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 Figure 4-5. The relative level of cell-associated virus is comparable for each 
SSTR-expressing cell line 
 
A. Equilibrium virus binding assay was performed using Sst-RBS MLV incubated with 
293 or SSTR-expressing cells (binding to 293 cells is unpublished data). Antiserum to 
the MLV glycoprotein was used to detect surface-bound virus by flow cytometry analysis. 
Representative histograms and values indicating the fold increase in MFI ± SD from 
three independent experiments are shown with surface-bound virus (purple) next to their 
mock-exposed counterparts (gray).  
 
B. Schematic showing the location of quantitative real-time PCR amplicons within the 
recombinant MLV genome used in infection experiments. U3, unique 3’ untranslated 
region, R, repeat sequence. U5, unique 5’ untranslated region. LacZ, β-galactosidase 
gene. SV40, simian virus 40 promoter. Neo r, neomycin resistance gene. 
 
C. Cells were exposed to Sst-RBS MLV or mock medium and spinoculated at 4 °C then 
shifted to 37 °C to allow internalization. After six hours unbound virus was removed and 
cells were lysed and isolated DNA was used directly as the template for quantitative 
real-time PCR. The level of cell-associated virus in the SSTR-expressing cells was 
determined as the relative fold increase of the MSS amplicon for each SSTR expressing 
cell line over the 293 signal (representing background binding) normalized to 
endogenous β-actin. No amplification was detected in mock-exposed cells. Data 
represent three independent experiments (n=3). Significance was calculated using one 
way ANOVA and Bonferroni posttest P value >0.5.  
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 importantly, in the amount of cell-associated virus that can account for the higher level of 
infection via SSTR-5. 
 
 
Infection of Sst-RBS Pseudovirions Requires Internalization 
 
Additional experiments were performed to investigate the nature of the differences 
in infection of the three receptor subtypes. WT MLV is internalized by caveolin-
associated endocytosis when bound to its natural receptor on NIH 3T3 cells [5], while 
the SSTR utilize clathrin-mediated endocytosis following SST-14 binding [30, 34]. To 
begin examining the possibility that internalization of Sst-RBS MLV bound to the three 
somatostatin receptor subtypes differs, infection was quantified in the presence of 
inhibitors of endocytosis (Figure 4-6A). Our lab [7, 43] and others [67, 73-75] have 
published the use of these inhibitors within the ranges indicated in this study with no 
detectable toxicity. To facilitate comparison to these previous publications, experiments 
were designed to use at least one “low” and “high” concentration within this range. 
Nocodazole, an inhibitor of microtubule polymerization that interferes with endocytic 
pathways used during virus entry. Nocodazole induced similar decreases in infection in 
all cell lines (Figure 4-6B), indicating that both WT and Sst-RBS MLV require 
endocytosis and, consequently, that the pseudovirions are not fusing at the cell surface.  
 
Infection was also carried out in host cells pre-incubated with methyl-β-cyclodextrin 
(MβCD) which sequesters cholesterol and disrupts lipid rafts. Cholesterol-dependent 
endocytic pathways are strongly inhibited by this drug. Interestingly, infection via 
SSTR-5 exhibited a mean inhibition of 43.0% to the lowest concentration of the drug that 
was similar to the level of sensitivity of control WT MLV on mCAT-1 in NIH 3T3 cells 
(mean of 37.9% inhibition). Infection of 293/SSTR-2 and -3 cells was also sensitive to 
MβCD (means of 18.3 and 24.4% inhibition, respectively) although the lower mean 
inhibitions were not statistically different from the means for SSTR-5 or NIH 3T3 (Figure 
4-6C). While these results confirm that internalization is required for entry via all three 
SSTR subtypes, it is also noteworthy that entry of Sst-RBS MLV through SSTR-5 
showed a cholesterol-dependence that was more similar to WT MLV on NIH 3T3 cells 
than to entry via the other two SSTR subtypes.  
 
 
A Slower Rate of Internalization Correlates with Enhanced Infection 
  
The efficiency of receptor internalization was evaluated by incubating the SSTR 
subtype expressing cell lines with 1 µM SST-14 or mock treatment for 30 minutes at 4 °C 
or 37 °C to stimulate receptor internalization. Cells were then incubated for 1 hour at 
4 °C with mouse anti-HA.11 monoclonal antibody (Figure 4-7A). A decreased MFI after 
treatment with 1 µM SST-14 was viewed as evidence that SSTR internalization 
occurred. The amount of internalization of each of the receptor subtypes at 4 °C (at 
which temperature receptor internalization should be inhibited) was then compared to 
the amount of internalization at 37 °C. The profile of 293 cells (which do not express any 
HA-tagged SSTR) does not change while the peaks for SSTR-2 and -3 reveal receptor 
internalization at 37 °C, each representing a mean fold increase in internalization of 27 
over that of control 293 cells. However, the peaks for SSTR-5 remain static, representing 
a mean fold increase in internalization of 8.8 (Figure 4-7B). This incongruence with  
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Figure 4-6. Infection of Sst-RBS pseudovirions requires internalization 
 
A. Experimental time line for drug inhibitor studies. 
 
B and C. 293, 293/SSTR-2,-3 and -5 or NIH 3T3 cells were pretreated with (B) DMSO, 
33 µM or 66 µM nocodazole for 1 hour or (C) H2O, 1 mM or 0.5 mM MβCD for 30 
minutes then exposed to Sst-RBS or WT MLV maintaining drug or vehicle. Infection was 
scored with Romanizer software for the presence of β-galactosidase positive cells at 48 
hpi. Relative infection was calculated as the percentage of infection compared to the 
vehicle only treated cells. No transduction was observed in 293 cells (data not shown). 
 
Data represent the mean ± SD of three independent experiments (n=4). P values were 
calculated by using two way ANOVA and Bonferroni posttest. NS, Not Significant; 
*, p ≤ 0.05; **, p ≤ 0.01.  
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 Figure 4-7. Patterns of receptor internalization among SSTR subtypes 
 
A. Experimental time line for receptor internalization study. 
 
B. Representative histograms indicating the level of cell surface receptor after 30 
minutes in the absence or presence of 1 µM SST-14 ligand at 4 °C or 37 °C as 
determined by flow cytometry using the HA epitope tag located on the amino-terminus of 
each SSTR subtype (unpublished data). 293 cells do not express HA tagged SSTR. 
Decreased MFI of peaks at 37 °C with 1 µM SST-14 indicate internalization of surface 
receptors.  
 
C. Relative internalization of HA-tagged SSTR in each cell line (unpublished data). The 
relative internalization was calculated by comparing the MFI of SST-14 treated cells at 
4 °C to the MFI of SST-14 treated cells at 37 °C and expressed as the mean fold 
increase in internalization, as indicated below the respective bar. 
 
Data represent the mean ± SD of three independent experiments. Significance was 
calculated by using two way ANOVA and Bonferroni posttest P value >0.5. 
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 infection results lead to the hypothesis that SSTR-5 was internalized more slowly than 
SSTR-2 and -3.  
 
Thus, the kinetics of virus-receptor complex internalization were directly investigated 
by examining the level of infection over time and under conditions in which virus 
attachment was synchronized and non-internalized virus was inactivated at early time 
points. Attachment was synchronized by spinoculation at 4 °C and internalization of 
bound virus was initiated by shifting the cultures to 37 °C. At various times after the 
temperature shift, non-internalized virus was inactivated by a low-pH citrate wash and 
infection was allowed to continue (Figure 4-8A). The level of transduction at each time 
point was normalized to the values obtained at one hour; at which time infection had 
reached an average of 92.1% of the levels obtained from overnight exposure of the 
same virus stocks on 293/SSTR-5 (data not shown). The normalized levels of 
transduction were graphed and the slope of each curve calculated by non-linear 
regression analysis to determine the relative rates of internalization (percentage per 
minute) for each virus-receptor combination. Surprisingly, Sst-RBS MLV was internalized 
faster in 293/SSTR-2 and -3 cells (Figure 4-8B) as indicated by 50% of infectious virus 
(T50) having been internalized at 12.4 and 13.3 minutes, respectively, compared to 19.7 
minutes in SSTR-5 expressing cells. Like the outcome of MβCD treatment, the T50 in 
SSTR-5 cells was similar to that of WT MLV in NIH 3T3 cells (17.7 minutes). No infection 
of either virus was seen in the parent 293 cells.  
 
 
SSTR-5 Directs Virus to a More Permissive Environment 
 
The differences in internalization presented in Figure 4-8 strongly suggest that entry 
through SSTR-5 may be directing Sst-RBS MLV to an intracellular environment that is 
more permissive for infection. To investigate this possibility, infection was examined in 
the presence of bafilomycin A1 (BafA) (a vacuolar ATPase inhibitor). This drug interferes 
with the acidification of endosomes and is commonly used to determine the pH 
requirements of the membrane fusion step during entry [55]. For example, WT MLV is 
not inhibited by BafA while VSV G mediated infection is profoundly decreased [73]. 
Unexpectedly, BafA enhanced, rather than reduced, infection through SSTR-2 (mean 
transduction increased from 2.9 ±1.6 TU/ml in DMSO treated cells to 7.5 ± 4.1 x 101 
TU/ml in cells treated with 10 nM BafA) and SSTR-3 (from 8.6 ± 3.1 to 22 ± 6.4 x 101 
TU/ml); whereas Sst-RBS MLV infection via SSTR-5 (from 2.6 ± 0.6 to 2.0 ± 0.9 x 103 
TU/ml) was not significantly affected by the drug (Figure 4-9A). While BafA enhanced 
infection via SSTR-2 and -3, the total amount of transduction remained logs below that 
seen in 293/SSTR-5 cells or in WT-MLV infection of NIH 3T3 cells. These results are 
consistent with exposure to an acidic environment, such as that found in late 
endosomes, inhibiting Sst-RBS MLV infection through SSTR-2 and -3 but not through 
SSTR-5. Results of infection in the presence of chloroquine (Chlor) (a weak base that 
accumulates in lysosomal compartments) were uninformative in that similar inhibition 
was observed in all cell types (Figure 4-9B). However, monensin had a more marked 
effect on infection in 293/SSTR-2 than BafA. A member of the carboxylic ionophore 
class of drugs monensin functions as a sodium ion exchanger also raising the pH of 
lysosomal compartments [6, 55, 76]. Infection through SSTR-2 increased from 13.4 ± 2.6 
to 124 ± 59.4 TU/ml in the presence of monensin which represents a 9.9 fold increase 
while infection of 293/SSTR-5 was unaffected in its presence (Figure 4-9C).  
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Figure 4-8. A slower rate of virion internalization correlates with increased 
infection 
 
A. Experimental time line for rate of internalization study. 
 
B. Sst-RBS or WT MLV was spinoculated onto 293, 293/SSTR-2, 3 and 5 or NIH 3T3 
cells at 4 °C then shifted to 37 °C for the indicated time to allow internalization. Non-
internalized virus was inactivated and infection measured at 48 hpi by counting LacZ 
positive cells using Romanizer software [44]. Values shown are the relative infection 
calculated as (infection at each time point / infection at one hour) x 100. The relative rate 
of internalization (% pseudovirions internalized per minute) was calculated as the slope 
of each curve using non-linear regression analysis (GraphPad Prism). T50, time required 
to obtain 50% infection.  
 
Data represent the mean ± SD of four independent experiments (n=4).  
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 Figure 4-9. Neutralizing acidic compartments enhances infection via SSTR-2 
 
A, B and C. 293, 293/SSTR-2,-3 and -5 or NIH 3T3 cells were pretreated with (A) 
DMSO, 10 nM, 20 nM, or 30 nM BafA (B) H2O, 15 µM or 30 µM Chlor or (C) EtOH, 12.5 
µM or 25 µM Monensin prior to Sst-RBS, VSV G or WT MLV exposure, as indicated, 
while maintaining the drug or vehicle. Infection was scored with Romanizer software for 
the presence of β-galactosidase positive cells at 48 hpi Relative infection was calculated 
as the percentage (A, B) or fold increase (C) of infection compared to the vehicle only 
treated cells. There was no observable infection of 293 cells in the presence or absence 
of chloroquine, but increased to 14 TU/ml at 10 nM BafA, and 14.77 ± 5.3 at 12.5 µM 
and 19.07 ± 4.3 TU/ml at 25 µM Monensin. 
 
All data represent the mean ± SD of at least three independent experiments (n=4). P 
values were calculated by using two way ANOVA and Bonferroni posttest. *, p ≤ 0.05; **, 
p ≤ 0.01.  
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 Since host cell proteases of the cathepsin family have been shown to be important 
in potentiating infection of WT MLV by activating the fusion capacity of the viral 
glycoprotein [7, 74], it is possible that SSTR-2 and -3 transport virus to intracellular 
compartments containing either an unfavorable type or concentration of protease. To 
examine this possibility, infection was performed in the presence of CA074 Me. At low 
concentrations, CA074 Me specifically inhibits cathepsin B, while at higher 
concentrations it also inhibits other cysteine cathepsins [7]. Infection of Sst-RBS MLV 
was reduced at the higher, non-specific concentration but was not changed significantly 
at 5 µM for all receptor subtypes, whereas; WT MLV infection of control NIH 3T3 cells 
was inhibited significantly at both concentrations (Figure 4-10A). These results suggest 
that, in a 293 cell background, cathepsin B is not the predominant protease involved in 
entry of Sst-RBS MLV. To further explore the influence of cellular proteases, infection 
was quantified in the presence of leupeptin, a lysosomal protease inhibitor. Sst-RBS 
MLV infection decreased markedly in 293/SSTR-2 and SSTR-3 while only modest 
decreases were seen in 293/SSTR-5 (Figure 4-10B), indicating that the protease 
involved in infection through SSTR-5 differs from those encountered by virus internalized 
via SSTR-2 and -3. Taken together, I favor the interpretation of these drug studies to 
indicate that SSTR-5 directs virus to a distinct intracellular compartment that is highly 
favorable for infection, at least in part because it contains a favorable set of cellular 
proteases for activation of the Sst-RBS glycoprotein. 
 
 
Penetration into the Host Cytoplasm Is More Efficient via SSTR-5 
 
If this interpretation is correct, then the greater infection via SSTR-5 could be 
explained by more efficient protease activation of virus-cell membrane fusion leading to 
greater levels of penetration. To test this hypothesis, the relative amount of virus that 
had penetrated the host cell cytoplasm was quantified. In MLV, reverse transcription is 
initiated during virion assembly but halts shortly after the MSS cDNA is generated. Then 
in a second stage, shown to occur after penetration, the cDNA of internal genes is 
synthesized [58, 72]. Based on this attribute, Gao and colleagues developed a 
quantitative real-time PCR assay using the amplification signal of an internal gene as a 
measure of virus penetration and infection [45]. We adapted this assay to compare 
penetration of MLV pseudovirions among the SSTR subtypes by measuring the level of 
internal LacZ gene amplification after 6 hours (Figure 4-11A). The schematic in Figure 
4-5B shows the location of the amplicon within the internal LacZ gene, as well as the 
MSS cDNA amplicon. The LacZ amplification signal for each cell line was normalized to 
the MSS signal for the zero and 6 hour incubation times to account for bound but not 
internalized virions. Increased LacZ amplification then becomes proportional to the 
number of virion cores that penetrate the host cytoplasm. When the normalized LacZ 
amplification data were expressed as the relative fold increase from zero to 6 hpi, 
293/SSTR-2 and -3 cells showed significantly lower levels of reverse transcription than 
293/SSTR-5 cells and NIH 3T3 cells exposed to WT-MLV over the 6 hour time period 
(Figure 4-11B). These data indicate that a partial block to reverse transcription occurred 
after virus binding and internalization into 293/SSTR-2 and -3 cells, supporting the 
interpretation that the endocytic pathway utilized by SSTR-5 directs virus to a more 
permissive environment for penetration.  
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Figure 4-10. SSTR-5 internalizes to a more permissive intracellular environment 
 
A and B. 293, 293/SSTR-2,-3 and -5 or NIH 3T3 cells were pretreated with (A) DMSO, 5 
µM or 25 µM CA074 Me or (B) H2O, 30 µg/ml or 100 µg/ml leupeptin prior to Sst-RBS, 
VSV G or WT MLV exposure, as indicated, while maintaining the drug or vehicle. 
Infection was scored with Romanizer software for the presence of β-galactosidase 
positive cells at 48 hpi Relative infection was calculated as the percentage of infection 
compared to the vehicle only treated cells. There was no observable infection of 293 
cells in the presence or absence of CA074 Me or leupeptin. 
 
All data represent the mean ± SD of at least three independent experiments (n=4). P 
values were calculated by using two way ANOVA and Bonferroni posttest. **, p ≤ 0.01.  
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Figure 4-11. Virus internalized via SSTR-5 more efficiently penetrates into the host 
cytoplasm 
 
A. Whole cell DNA was isolated from 293, SSTR-expressing and NIH 3T3 cells exposed 
to Sst-RBS or WT MLV. DNA was isolated from cells incubated with virus at 4 °C but not 
shifted to 37 °C and from replicate cell cultures 6 hours after a 37 °C shift to allow 
internalization, membrane fusion and viral nucleocapsid penetration of the host cell 
cytoplasm as indicated in the experimental time line.  
 
B. Results obtained from the MSS and LacZ amplicons were normalized to the β-actin 
signal for the respective host cell line and the fold increase in the level of reverse 
transcription was calculated as a measure of virion penetration by comparing LacZ gene 
amplification to the MSS amplification signal over the 6 hour time period. No 
amplification was detected in mock-infected cells.  
 
Each symbol represents the relative fold increase in pseudovirion penetration from one 
independent experiment. The mean relative fold increase from six independent 
experiments is shown below the graph (n=3). P values were calculated using one way 
ANOVA and Dunn’s posttest. **, p ≤ 0.01.  
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 Discussion 
 
This chapter reports observable differences in the level of infection of Sst-RBS 
pseudotyped retroviruses when exposed to 293 cells stably expressing somatostatin 
receptor subtypes 2, 3 and 5 (Figures 4-2A and B) that correlate with distinctive 
receptor subtype-specific characteristics. When facilitated by SSTR-2 and -3, infection is 
restricted at a point after receptor binding and internalization (Figures 4-5 and 4-6B) but 
prior to penetration into the host cytoplasm (Figure 4-11). In contrast, SSTR-5 mediated 
entry featured slower internalization with characteristics similar to that observed for WT 
MLV (Figures 4-7 and 4-8). Virus bound to SSTR-5 was directed to an intracellular 
environment that allowed near WT levels of penetration (Figure 4-11) possibly due to a 
more favorable complement of host cell proteases (Figure 4-10). 
 
Taken together I interpret these results to support that the observed differences in 
infection between SSTR subtypes are primarily due to differences in the fate of 
internalized virus-receptor complexes. I favor that the intracellular trafficking patterns 
accessible to each subtype impose constraints on internalized virus-receptor complexes 
and direct viruses to more, or less, permissive environments. Figure 4-12 shows a 
model of virus entry illustrating these observations and the proposed pathways used by 
the SSTR subtypes. This interpretation is consistent with reports of agonist-induced 
SSTR desensitization (natural ligand removal and receptor recycling or degradation). 
While SSTR-2, -3 and -5 are similar in structure, kinetics of agonist binding and 
internalization [30], the subtypes differ in their intracellular trafficking during 
agonist-induced desensitization. SSTR-5 lacks the clusters of Ser/Thr phosphate 
acceptor sites found on the cytoplasmic tails of subtypes 2 and 3 [30, 34, 77]. These 
clustered phosphate acceptor sites have been shown to control the intracellular 
destination of ligand-SSTR complexes by regulating β-arrestin and scaffolding protein 
recruitment to endocytic vesicles resulting in distinct intracellular fates for the 
internalized ligand-receptor subtype complexes [30, 36, 77].  
 
Inhibition during virus binding and internalization would represent relatively trivial 
explanations for the different levels of infection observed among the somatostatin 
subtype expressing cell lines; whereas effects on fusion and penetration are of greater 
interest. A standard virus binding assay was unable to detect Sst-RBS MLV binding to 
any of the SSTR subtypes that was above the level of binding to control 293 cells, and 
the relative amount of cell-associated virus was similarly uninformative (Figure 4-5). 
However, there was an extremely large difference in the LacZ transducing units between 
SSTR-2 and SSTR-5 (222 fold, Figure 4-2). If this were due to a higher percentage of 
virions binding and internalizing in 293/SSTR-5 cells it is likely that that either the 
standard binding and/or the more sensitive quantitative real-time PCR assay would 
reflect this. Instead, it is possible that these data reflect non-specific binding [78] and 
endogenous SSTR-2 receptor expression in 293 cells [79] which, under the typical 
infection conditions used in this study, do not permit transduction. However, transduction 
in 293 cells was enhanced under the same conditions as 293/SSTR-2 (see Figure 4-9 
legend) indicating that binding and internalization does occur in 293 cells and low levels 
of infection can be detected under neutralizing conditions. For this reason the amount of 
cell-associated virus was normalized to account for virus that may be associated with the 
SSTR expressing cell lines because of their 293 parentage. When these data are 
expressed as the fold increase compared to the amount of cell-associated virus in the 
293 cells no differences amongst the cell lines were observed that can account for the 
increased transduction via SSTR-5.  
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Figure 4-12. Model of the influence of intracellular destination on infection 
 
Thick arrows indicate that comparable amounts of Sst-RBS pseudotyped virus are 
internalized by each SSTR subtype. Thin arrows indicate that a large percentage of 
virions complete penetration, reverse-transcription and integration when internalized via 
SSTR-5. Dashed arrows indicate that a relatively small percentage of virions internalized 
via SSTR-2 and -3 complete critical late steps of entry into the host cell cytoplasm for 
infection. The infection characteristics observed for each SSTR subtype are listed next 
to the corresponding entry pathway.  
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 If Sst-RBS LV pseudovirions had shown comparable levels of infection among the 
cell types despite the fact that the MLV pseudotypes were divergent, then this would 
suggest that the critical step in infection of these virions was dependent on the core 
particle or genome of the virus (Figure 4-2). On the contrary, these data strongly 
indicate that the differences in infection are envelope dependent. Since the Sst-RBS 
glycoprotein is the same in both the LV and MLV pseudovirions and infection was 
competitively inhibited in each of the SSTR expressing cell lines, the receptor subtype is 
the most likely variable that could affect such an influence. 
 
Multiple lines of evidence presented here indicate that Sst-RBS pseudovirions 
internalized via SSTR-5 utilize a distinct intracellular trafficking pattern from that used by 
SSTR-2 and 3. First, although each of the SSTR-expressing cell lines displayed a 
dependence on host cell cholesterol for endocytosis, transduction via SSTR-5 was as 
sensitive to MβCD cholesterol depletion as infection of WT MLV via mCAT-1 on NIH 3T3 
cells (Figure 4-6C) in which mCAT-1 co-localizes with caveolin during internalization [5]. 
Second, Sst-RBS pseudovirions internalized at a slower rate in 293/SSTR-5 cells than in 
the SSTR-2 and -3 lines (Figures 4-7 and 4-8). Third, infection of 293/SSTR-2 and -3 
cells increased significantly in the presence of BafA and monensin, whereas infection of 
293/SSTR-5 cells was not affected by these inhibitors of vesicular acidification (Figure 
4-9A and C). In accordance, HIV-1 infection has been shown to increase in the presence 
of BafA, an effect that the authors attributed to inhibition of lysosomal acidification that 
slowed the degradation of virus particles to allow more time for membrane fusion [65]. 
Viejo-Borbolla and coworkers also proposed a similar explanation for their finding that 
infection of a modified Moloney MLV glycoprotein retaining the use of mCAT-1 was also 
increased in the presence of BafA [80]. 
 
While I favor that the entry pathway used by Sst-RBS MLV bound to SSTR-2 and -3 
exposes virions to a more destructive set of proteases than those entering via SSTR-5, it 
is also possible that the acidic nature of these compartments may influence the structure 
of the Env glycoprotein making it more susceptible to inactivation by cellular proteases 
or less attractive to proteases involved in activating membrane fusion. The extent to 
which leupeptin inhibited infection of 293/SSTR-2 and -3 cells (Figure 4-10B) indicates 
the importance of lysosomal proteases in these entry pathways. The parasitic nature of 
viruses, in particular those such as MLV that rely on host proteases to potentiate the 
conformational changes required for efficient entry (in contrast to those like VSV whose 
requirements rely strictly on acidic pH), means that they walk a fine line between 
potentiation and degradation by these same proteases. Raising the pH of intracellular 
compartments requires the proteases to function sub-optimally and shifts the dynamic to 
favor virus entry instead of degradation. However, leupeptin directly inhibits these 
lysosomal proteases revealing that they are indeed responsible for the results observed 
in this study. The observation that lysosomal proteases do not appear to be involved in 
infection via SSTR-5 is further evidence that this receptor delivers virions to a more 
permissive compartment because it lacks degradative enzymes. The redundant nature 
of these proteases, limited specificity of available inhibitors and lack of viable knock-out 
cell lines make it difficult to determine exactly which protease is acting on virus 
internalized by SSTR-2 and -3. However, possible candidate proteases are most likely in 
the same class of cysteine proteases as cathepsin B, such as the lysosomal proteases 
cathepsin H and cathepsin L1 since transduction in the presence of the inhibitor 
CA074 Me showed similar levels of inhibition among the SSTR-expressing cells (Figure 
4-10A). Regardless, the results of the drug and protease inhibitor studies, along with the 
differing rates of internalization during early entry, are consistent with SSTR-2 and -3 
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 rapidly directing virus to a degradative compartment. In contrast, the patterns observed 
for SSTR-5 suggest that it internalizes into a non-acidic environment (unaffected by 
BafA) where it might persist for a longer period of time. 
 
Several alternative interpretations were ruled out for the reasons stated below. First, 
the increased titer might be explained if SSTR-5 allowed membrane fusion to occur at 
the cell surface. A precedent for MLV surface fusion was established in rat XC sarcoma 
cells [81] in which WT-MLV infection was shown to occur independently of microtubule 
polymerization [43]. However surface fusion is unlikely in 293/SSTR-5 cells since 
nocodazole inhibited infection indicating that microtubule polymerization is involved 
(Figure 4-6B), a trait common to most endocytic mechanisms [55]. A second alternative 
might be that the comparable levels of cell surface receptors detected by flow cytometry 
using the HA epitope tag did not reflect the actual quantity available to bind virions nor 
their capacity for internalization. For example, when SSTR-5 was exogenously 
expressed in COS-7 cells, ligand binding resulted in internalization but surface SSTR-5 
was quickly replenished by a combination of mobilization from intracellular pools and 
receptor recycling [37]. In addition, if the exogenous expression of receptors in 293 cells 
resulted in a stochastic limitation of the endocytic adaptor proteins, then the capacity of 
subtypes 2 and 3 for internalization could be compromised. If either condition occurred 
then a significant difference in the quantity of cell-associated and internalized virions 
would be expected between the subtypes. However, quantitative real-time PCR of the 
MSS DNA revealed that similar quantities of Sst-RBS pseudovirions associated with 
293/SSTR-2, -3 and -5 cells during a 6 hour exposure (Figure 4-5C), supporting the 
interpretation that the quantity of effective receptors and their capacity for internalization 
were comparable amongst the subtypes. 
 
Previous studies suggested that the internalization pathway can influence infection 
of enveloped and non-enveloped viruses. Under normal conditions, ASLV-A infection is 
equally efficient using the glycosylphosphatidylinositol (GPI)- and transmembrane-
anchored isoforms of its cellular receptor TVA [68] and viruses traffic to the same 
intracellular compartment [69]. However, prolonged exposure of host cells to ammonium 
chloride alters infection, reducing it for both receptor isoforms but to different degrees, 
resulting in infection that is relatively greater using GPI-anchored TVA than the 
transmembrane-anchored isoform [68]. In this perturbed system, viruses were trafficked 
to different intracellular compartments that were apparently less permissive than the 
compartment to which the virus normally traffics [69]. However, the ammonium chloride-
treated cells showed abnormal intracellular compartment morphology and altered 
subcellular localization of vesicular trafficking proteins [69] leaving open the question of 
how much of the observed differences were relevant to natural infection as versus due to 
pleiotropic effects of the prolonged exposure to ammonium chloride. Other evidence 
comes from studies of rotaviruses. Strains of these non-enveloped viruses use a number 
of different cellular receptors, with the choice of receptor being specified by differences 
in the VP4 spike protein. Interestingly, a study of the strain-specific diversity of VP4 
revealed a strong bias toward use of receptors that internalize by clathrin-mediated 
endocytosis [82]. However, this study did not address if receptors using this endocytic 
pathway delivered viruses to the same compartment or if the clathrin-dependent bias 
could have evolved because this pathway is more productive for rotaviruses. 
 
I examined the early entry stages of infection in an effort to more concisely 
investigate if the intracellular trafficking of internalized virus-receptor complexes affected 
the efficiency of infection. These studies were begun by generating a set of cell lines that 
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 provided a system in which the predominant influence on infection would be differences 
in intracellular trafficking of internalized virus-receptor complexes, thereby circumventing 
the major technical constraints that have limited previous studies. Regardless of why the 
intracellular destination varied between receptor subtypes, one subtype delivered virus 
to a distinct compartment from which a significantly higher percentage of virions 
penetrated into the host cell cytoplasm. The results directly demonstrate that the 
intracellular trafficking pathways of a virus receptor can have profound effects on the 
level of infection. Furthermore, opportunities for more efficient infection presented by 
intracellular trafficking to more, or less, permissive intracellular environments exerted 
selective pressure on the choice of a cellular protein as a receptor during viral spike and 
glycoprotein evolution.  
 
The notion that retroviral glycoproteins and their cellular receptors co-evolved is 
significant when developing targeted viral vectors. The conformational changes of the 
Env glycoprotein that are required to initiate infection likely occur only under conditions 
that mimic the natural virus-receptor relationship. This implies that the placement and 
structure of the targeting ligand within the glycoprotein are important, but it also suggests 
that the choice of the targeted receptor should also be carefully considered. This 
research indicates that targeting to a receptor which internalizes to an intracellular 
destination with similar properties as the destination of the natural virus-receptor 
complex will allow for the highest transduction capacity. 
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 Chapter 5. In Vivo Gene Transduction with Sst-RBS Pseudotyped Lentivirus§ 
 
 
Introduction 
 
The capacity to transduce cells endogenously expressing SSTRs in vivo is the next 
logical step in characterizing the Sst-RBS glycoprotein for use as an in vivo vector. The 
brain was chosen as the target tissue for these studies because of its immunologically 
privileged status ensuring that immune responses to the viral vectors would be restricted 
in the immunocompetent subjects. Additionally, effective treatments have been difficult 
to attain for the neurodegenerative symptoms of diseases such as the well-known 
Alzheimer’s disease (AD), Huntington’s disease (HD) and Parkinson’s disease (PD) 
since drug compounds only mask symptoms and fail to address the underlying causes of 
these diseases. A related group of diseases which lack treatment for neurodegenerative 
effects are lysosomal storage diseases (LSD) such as Mucopolysaccharidosis (MPS) VII 
which results from a deficient β-glucuronidase (GUSB) enzyme. The deficiency leads to 
an accumulation of glycosaminoglycans in lysosomal compartments. Affected individuals 
develop pathologies such as organomegaly, progressive skeletal abnormalities and 
neurological and cognitive dysfunctions [83] ranging in severity depending on the nature 
of the enzyme deficiency [84]. Protein and enzyme replacement therapies (ERT), while 
effective for treating the systemic progression of disease, have had no effect on 
neurological symptoms due to the extremely limited ability for these treatments to cross 
the blood brain barrier (BBB) and gain access to the central nervous system (CNS) [85-
87]. These reasons make neurodegenerative diseases good candidates for treatment 
with lentiviral directed gene therapies. 
 
SSTR are present in several regions of therapeutic interest in the brain including the 
choroid plexus (ChP), ependymal cells lining the ventricular system, dentate gyrus of the 
hippocampus (DG), corpus striatum, substantia nigra and subthalamic nucleus in the 
brain [88, 89] and therefore should be capable of transduction by Sst-RBS pseudotyped 
lentivirus particles. These regions would also be susceptible to transduction via VSV G 
pseudotyped vectors but its broad tropism might actually be detrimental in the treatment 
of these diseases. While it may seem reasonable to use a vector with the ability to 
transduce nearly all the cells it encounters; this activity works more like a sponge, 
soaking up large quantities of available vector, preventing its dispersal. In practice, a 
large area of partially transduced cells may be preferable. Several studies delivering 
GUSB to brain cells of deficient mice indicate that direct transduction of the GUSB gene 
to all cells was not required to provide sufficient therapeutic benefit; as disease reversal 
was observed even in non-transduced cells [90, 91]. The following study is an 
investigation into the feasibility of in vivo delivery and a comparison of the ability of 
Sst-RBS and VSV G pseudotyped virions to disperse into the brain parenchyma.  
 
 
 
§ Adapted with permission.  Li, F., B. Y. Ryu, R. L. Krueger, S. A. Heldt and L. M. 
Albritton.Targeted entry via somatostatin receptors using a novel modified retrovirus 
glycoprotein that delivers genes at levels comparable to those of wild-type viral 
glycoproteins. J Virol, 2012. 86(1): 373-381. 
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 Results 
 
 
Proof of Principle for In Vivo Gene Transduction by Sst-RBS Pseudotyped 
Lentivirus Particles 
 
A pilot assay to determine the feasibility of intracranial delivery was performed by 
microinjecting 2 µl of a concentrated stock of HIV-based SIN lentiviral vector bearing 
either Sst-RBS or VSV G glycoproteins and transducing the red fluorescent protein 
mKate2 into the subthalamic nucleus of one hemisphere of two mice. Three days post 
injection the brain tissue was harvested and 20 µm frozen coronal sections were 
analyzed at a magnification of 200X for the presence of mKate2 fluorescence. No red 
fluorescence was observed in hemispheres that did not receive an injection in either the 
Sst-RBS or VSV G LV exposed mouse (Figure 5-1A). In the contralateral hemisphere of 
the VSV G LV injected mouse, numerous red fluorescing mKate2-transduced cells were 
present along the lower length of the injection pathway or “needle track” (Figure 5-1B). 
In contrast, the same length of needle track in the Sst-RBS LV injected mouse showed 
very few red fluorescent cells but a burst of transduction was observed at the end of the 
needle track in the region of the SN (Figure 5-1C). The area directly above the SN is 
reportedly negative for SSTR expression [88, 89, 92], however the cellular receptor 
recognizing VSV G is present throughout these regions [93]. This provides proof 
principle that Sst-RBS LV does indeed transduce murine brain cells and may represent 
targeted transduction of SSTR positive cells since a majority of red fluorescence was 
observed at the end of the needletrack in a region reported to express SSTR [88] while 
VSV G LV transduced cells in both SSTR expressing and non-expressing regions. The 
level of transduction observed in the VSV LV injected mice was dramatically higher even 
in the SN region. This was to be expected since these lentiviral stocks displayed an 
approximate 200-fold difference in luciferase TU/ml (Figure 3-1). Based on these 
observations, the concentrated VSV G LV stock was diluted 100 fold in PBS prior to 
injection in subsequent experiments. 
 
 
SSTR-2 Expression in the Murine Brain 
 
Historically, investigations into the expression of SSTR in the rat and mouse brain 
have been confined in situ hybridization to localize SSTR subtype mRNA expression or 
autoradiography using radiolabeled synthetic ligands [88, 92]. More recently, rat models 
have been used to directly address the level of SSTR surface expression in brain cells 
with subtype specific antibodies [89]. In an effort to determine where in the mouse brain 
SSTR surface expression is located, coronal sections were co-stained with a rabbit 
monoclonal antibody to SSTR-2 and a mouse monoclonal antibody to the neuronal cell 
nuclear membrane protein, NeuN. Several areas of positive SSTR-2 staining were 
immediately evident and corresponded to previous reports. These areas were the 
cerebral cortex layers IV, V and VI; the caudate putamen which comprises the corpus 
striatum in the mouse; the ependymal cells lining the lateral and third ventricles (Figure 
5-2A); the dentate gyrus of the hippocampus and the medial habenula (Figure 5-2B). 
 
Sections were evaluated for co-expression of SSTR-2 and NeuN at a higher 
magnification (200X). In the cortex (Figure 5-3A) and striatum (Figure 5-3B and 5-3C) 
the SSTR-2 positive cells co-stain with the NeuN neuronal marker, however not all NeuN 
positive cells co-stain with SSTR-2 suggesting that, while neurons are the 
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Figure 5-1. Proof of principle for in vivo gene transduction by Sst-RBS 
pseudotyped lentivirus 
 
Phase contrast images and corresponding mKate2 fluorescence of the uninjected (A) or 
injected (B and C) hemispheres of mice exposed to VSV G or Sst-RBS lentivirus 
transducing mKate2. The coronal murine brain section and arrow to the left is presented 
to indicate the injection trajectory of the representative micrographs at the right. Tissue 
sections from 9-12 week old mice were microinjected with 2 µl of Sst-RBS or VSV G 
pseudotyped LV transducing the red fluorescent protein marker, mKate2, in the 
subthalamic nucleus. Three days later mice were sacrificed and 20 µm frozen coronal 
sections imaged at 200X magnification on a Zeiss Deconvolution microscope. Multiple 
image frames were carefully aligned to provide a complete image of the needle track.  
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Figure 5-2. SSTR-2 receptors are expressed in the murine brain 
 
A and B. Coronal sections through the septo-diencephalic (A) and rostral diencephalic 
(B) regions from 9-12 week old mice were co-stained with Hoechst nuclear stain (blue), 
monoclonal mouse anti-NeuN neuronal marker and goat anti-mouse Alexa-647 (purple), 
monoclonal rabbit anti-SSTR2 and goat anti-rabbit Alexa-488 (green). Micrographs were 
imaged by Aperio ScanScope at 6X magnification. SSTR-2 positive regions of interest 
labeled: CC, Cerebral Cortex; CP, Caudate Putamen of the Corpus Striatum; LtV, 
Lateral Ventricle, DG, Dentate Gyrus of the Hippocampus H, Habenula (medial).  
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Figure 5-3. SSTR-2 receptors are expressed on neurons of the murine brain 
 
A, B and C. Some, but not all, cortical (A) and striatal (B-C) cells co-stain with the 
neuronal marker NeuN and surface expression of SSTR-2. Coronal murine brain 
sections and white boxes to the left are presented to indicate the area from which the 
micrographs at the right were taken. 20 µm frozen coronal sections from 9-12 week old 
mice were co-stained with Hoechst nuclear stain (blue), monoclonal mouse anti-NeuN 
and goat anti-mouse Alexa-594 (red), monoclonal rabbit anti-SSTR-2 and goat anti-
rabbit Alexa-488 (green). Micrographs were imaged on a Zeiss Deconvolution 
microscope at 200X magnification.  
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 primary cell type expressing SSTR-2 in these areas, only certain neuronal types do so. 
Interestingly, the ependymal cells lining the lateral (Figure 5-4A) and third ventricles 
(Figure 5-4B) also express SSTR-2; however, ependymal cells are of a glial lineage. 
They stain positively for glial fibrillary acidic protein (GFAP) and do not express NeuN 
[94]. Co-staining sections with antibody recognizing the GFAP and SSTR-2 was not 
possible during the course of these studies because both primary antibodies were 
produced in rabbit hosts. Therefore it is possible that other cells of glial lineage may also 
express surface SSTR-2. 
 
 
Sst-RBS Lentivirus Mediated Transduction in the Murine Brain 
 
 The lateral ventricle of a mouse injected with 2 µl of concentrated Sst-RBS LV 
vector was evaluated for the presence of mKate2 transduction in cells expressing 
surface SSTR-2. The injection trajectory of this mouse was originally intended to target 
the striatum, not the area surrounding the ventricle. However, the variable nature of 
working with individual subjects is such that this particular injection was sufficiently close 
to the ventricle that transduction was observed in SSTR-2 expressing cells in the region 
of the lateral ventricle. This included the NeuN negative ependymal cells (Figure 5-5).  
 
 Transduction was also observed in the striatum of mice injected with 2 µl of 
approximately equal luciferase transducing units of Sst-RBS LV or VSV G LV. 
Representative images of mKate2 transduction along the needle-tracks of both vectors 
are shown in Figure 5-6A and B. VSV G LV mediated mKate2 transduction was 
observed to be heavily concentrated around a central core with little diffusion into the 
surrounding area. In contrast, the core transduction of Sst-RBS LV was less dense but 
larger in overall area; suggesting that the Sst-RBS LV vector possessed a greater 
capacity for diffusion in this region of the brain. The area of mKate2 transduction from 
three Sst-RBS and VSV G LV injected mice was determined using Image J software 
analysis. The mean area of mKate2 transduction did not differ significantly between the 
mice injected with Sst-RBS or VSV G pseudotyped vectors, indicating that Sst-RBS 
pseudotyped lentiviral vectors have a comparable transduction capacity as VSV G 
vectors in vivo. 
 
 The transduction zones (TZ) of multiple sections from three mice injected with 2 µl 
of either the Sst-RBS or VSV G pseudotyped LV vectors were quantified by measuring 
the height and width of the core and maximum TZ and calculating the ellipsoidal area. 
The core TZ was defined as the area with the highest concentration of mKate2 
expression and the maximum TZ as the largest overall area of mKate2 expression. 
Additionally, transduction from the contralateral hemisphere of each mouse was 
measured. These hemispheres were injected with 2 µl of either Sst-RBS or VSV G LV 
vectors immediately after the injection of 0.5 µl of 100 µM SST-14 peptide, which inhibits 
Sst-RBS but not VSV G mediated transduction (Figure 4-3). The mean core 
measurements of both Sst-RBS LV exposed hemispheres were comparable as were the 
core measurements of the VSV G treated mice in the presence and absence of the 
peptide. Interestingly, the mean Sst-RBS core TZs were larger than the VSV G cores 
(Figure 5-7A to E). When the maximum TZs were measured, the untreated Sst-RBS 
and VSV G zones were comparable in size, but the mean TZ of the hemispheres 
pre-treated with SST-14 prior to Sst-RBS LV exposure were slightly smaller than their 
untreated counterparts. As expected, SST-14 pre-treatment had no effect on the 
maximum TZ area of VSV G (Figure 5-7F to J). Even though this was a small sample  
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Figure 5-4. SSTR-2 receptors are expressed on murine ependymal cells 
 
A and B. Ependymal cells lining the lateral (A) and third ventricles (B) of the murine brain 
do not stain positively for the neuronal marker NeuN, but express the SSTR-2 receptor. 
Coronal murine brain sections and white boxes to the left are presented to indicate the 
area from which the micrographs at the right were taken. 20 µm frozen coronal sections 
from 9-12 week old mice were co-stained with Hoechst nuclear stain (blue), monoclonal 
mouse anti-NeuN and goat anti-mouse Alexa-594 (red), monoclonal rabbit anti-SSTR-2 
and goat anti-rabbit Alexa-488 (green). Micrographs were then imaged on a Zeiss 
deconvolution microscope at 200X magnification.  
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Figure 5-5. Sst-RBS lentivirus mediated transduction of murine ependymal cells  
 
SSTR-2 positive murine ependymal cells colocalize with Sst-RBS-mediated mKate2 
marker transduction. The coronal murine brain section and red arrow to the left is 
presented to indicate the injection trajectory of the representative micrographs at the 
right. Tissue sections from 9-12 week old mice were microinjected with 2 µl of Sst-RBS 
pseudotyped lentivirus transducing the fluorescent protein marker mKate2 (red) in the 
caudate putamen. Three days later mice were sacrificed and 20 µm frozen coronal 
sections co-stained with monoclonal rabbit anti-SSTR-2 and goat anti-rabbit Alexa-488 
(green) and monoclonal mouse anti-NeuN and goat anti-mouse Alexa-647 (purple). 
Micrographs were imaged by Aperio Scanscope at 50X and 200X magnification.  
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Figure 5-6. Sst-RBS and VSV G lentivirus mediated transduction along the 
needle-tracks in the striatum of mice 
 
A, B and C. Representative mKate2 (red) transduction zones from Sst-RBS (A) or VSV 
G (10-2 TU/ml) (B) pseudotyped lentivirus microinjected into the caudate putamen of 9-
12 week old C57bl/6 mice. Three days later mice were sacrificed and 20 µm frozen 
coronal sections were stained with Hoechst nuclear stain (blue) and micrographs imaged 
by Aperio Scanscope at 34X magnification. (C) The area of mKate2 transduction from 
three Sst-RBS LV (purple) or VSV G LV (white) injected mice was determined using 
Image J software. The mean and SD of mKate2 transduction is shown (n=3).  
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 Figure 5-7. Transduction zone diffusion of Sst-RBS and VSV G lentivirus 
particles in intracranially injected mice 
 
A through L. Mice were microinjected in the caudate putamen with 2 µl of concentrated 
mKate2 transducing lentivirus coated with Sst-RBS or VSV G (10-2 TU/ml) in the 
presence or absence of 100 µM SST-14 ligand. Three days post infection, the mice were 
sacrificed, and 20 µm frozen tissue sections were analyzed for mKate2 expression (red). 
Aperio Scanscope images were measured for core (A-E) and maximum (F-J) 
transduction zone areas. The mean ± SD for three mice are shown in A and F. 
Representative images for Sst-RBS (B,C, G, H) and VSV G (D,E,I,J) zones are shown 
indicating mKate2 expression as well as areas of no transduction from comparable 
sections for Sst-RBS (K) and VSV G (L). 
 
One Way ANOVA and Bonferroni posttest used to determine P-value > 0.05; NS, Not 
Significant. 
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 size (n=3), some guarded conclusions could be drawn from these observations. First, 
the larger core TZ area of Sst-RBS LV suggests that it was capable of diffusing away 
from the injection site into the surrounding brain tissue while the VSV G LV particles 
were immediately adsorbed onto cells in the vicinity of the injection site. Second, the 
comparable maximum TZs of hemispheres exposed to virus in the absence of SST-14 
suggest that VSV G LV particles escaping adsorption at the injection site were capable 
of diffusing the same distance as Sst-RBS LV particles. In general, however, the VSV G 
TZs had a more distinct core and less distinct maximum area; whereas, the Sst-RBS 
TZs were more uniform in intensity throughout both measurement areas. Third, the 
decrease in maximum TZ area of Sst-RBS LV in the presence of SST-14, although not 
statistically significant, can be interpreted to indicate that transduction was specifically 
mediated by the presence of SSTR.   
 
 
Discussion 
 
This study demonstrated proof of principle for in vivo Sst-RBS mediated 
transduction in the murine brain (Figure 5-1) which displayed comparable transduction 
efficiency to VSV G pseudotyped vectors (Figures 5-6 and 5-7). Several regions of 
interest in the murine brain stain positively for SSTR-2 surface expression (Figure 5-2) 
and SSTR-2 is expressed on some classes of neurons (Figure 5-3) as well as 
ependymal cells which line the ventricular system (Figures 5-4 and 5-5). These 
observations suggest several areas of potential clinical relevance for the chimeric Sst-
RBS glycoprotein. The subthalamic nucleus is involved in PD and has also been 
implicated in AD [95]. Additionally, transduction of cells in the striatum indicates that this 
new chimeric glycoprotein may be useful as a therapeutic and investigational tool for AD 
and HD as well as other neurodegenerative diseases involving these regions of the brain 
such as LSDs.  
 
Enzyme replacement therapies (ERT) have been developed for several LSDs 
including Gaucher disease, Fabry disease, Pompe disease, MPS I, MPS II and MPS VI 
[86, 96] based on the discovery that a small amount of proenzyme is naturally excreted 
during transport from the TGN to lysosomes and can be taken up either by the original or 
a neighboring cell by the mannonse-6-phosphate receptor (M6PR) [97, 98]. However, 
with the exception of Gaucher disease [86, 99], ERT has only been moderately 
successful since it requires life-long treatments of exogenously produced recombinant 
enzymes [87] and because intravenously administered enzyme is inefficiently delivered 
to target cells. A majority of recombinant enzymes collect in reticuloendothelial cells of 
the liver and spleen [86] and are incapable of crossing the BBB for delivery to the CNS 
[86, 96]. The latter is a particular concern for LSDs that manifest with severe 
neurodegeneration such as MPS VII. Directly injecting enzyme into the cerebrospinal 
fluid (CSF) may be a means of circumventing the BBB, but this approach still remains 
impractical due to the long-term nature of ERT [86]. 
 
Advances in gene therapy are a promising direction for the treatment of neurological 
diseases and LSDs. Both systemic and direct CNS delivery of viral vectors including 
adenovirus (ADV), adeno-associated (AAV), RV and LV vectors have successfully 
transduced target genes providing long-term protein expression (for review see [96]). 
RVs and LVs are particularly useful due to their ability to integrate into host 
chromosomes thus alleviating the continious nature of ERT. Typically, intravenous 
delivery of GUSB expressing vectors results in transduction of liver and spleen cells 
60 
 which are then capable of secreting enough cross-protective enzyme into the 
bloodstream that therapueutic benefits were observed in the peripheral organs and 
skeleton [100-103]; however, transport across the BBB is not evident [96, 100, 102]. In 
contrast, direct injection into the CNS has been shown to be effective at long term 
expression of marker and therapeutic genes by ADV, AAV and VSV G pseudotyped RV 
and LV delivery methods [90, 91, 96, 104]. While ADV, AAV and LV particles were 
capable of transducing both NeuN postive neurons and GFAP postive glial cells (VSV G 
pseudotyped RV was not capable of transducing the terminally differentiated neurons), 
VSV G pseudotyped LV was by far the most efficient. The LV transduced more 
cells/mm3 than the other vectors with approximately 89% of all transduced cells identified 
as NeuN positve neurons [105]. The present study suggests that the Sst-RBS targeting 
LV is at least as capable of trandsduction as the VSV G LV when approximately equal 
TU/ml were compared (Figure 5-7F). Moreover, the Sst-RBS LV may be preferrable. 
Due to its targeted nature it displayed a greater potential for diffusion away from the 
initial injection site (Figure 5-7A). 
 
SSTR mRNA and surface expression have been demonstrated throughout the 
murine and rat brain. Whereas SSTR-2 and -3 are the predominant subtypes expressed, 
SSTR-1 and -4 are also expressed and to a far lesser extent SSTR-5. [88, 89, 92]. This 
study only investigated the expression of SSTR-2 in the murine brain as an initial 
indication of feasibility. Since the SST-14 ligand displayed by the Sst-RBS glycoprotein 
is equally capable of binding and internalizing through subtypes 2, 3 and 5 (Figure 4-5), 
transduction might occur via any of the SSTR subtypes in vivo.  
 
It was surprising to note that Sst-RBS mediated transduction was as efficient in vivo 
as VSV G (Figure 5-6) given that SSTR-5 expression in the brain is reportedly extremely 
low and in vitro transduction was significantly greater via this subtype than SSTR-2 and-
3 (Figure 4-2), the predominant subtypes expressed in the brain [88, 89]. This suggests 
that, at least in the brain, in vitro studies may not correlate with in vivo transduction. 
Since the presence of only one SSTR subtype, SSTR-2, was evaluated during this 
preliminary investigation; this level of Sst-RBS mediated transduction might represent 
the use of several SSTR subtypes as multiple SSTR expression has been reported [88, 
89]. Further studies will need to be performed in order to assess the expression of each 
SSTR subtype in lentivirus transduced brain cells. Additionally, the highly specialized 
nature of neurons may further account for this disconnect. Their unique shape and size 
means that their intracellular trafficking patterns are prolonged compared to other cell 
types [106, 107]. Moreover, their low turn-over rate, limited access to extracellular 
nutrients and need to heavily regulate their membrane and cytoplasmic contents set 
extreme limits on cellular resources. One of the many ways neurons have developed to 
compensate for these requirements is a highly ordered endosomal and lysosomal 
system. [106-108]. Indeed, the lysosomal compartments of neurons are exquisitely 
sensitive to perturbation as evidenced by their involvement in almost every 
neurodegenerative disease including those discussed above. In an effort to conserve 
resources, neuronal cells often slowly recycle signaling receptors such as SSTRs 
instead of downregulating them through lysosomal degradation [107, 108]. In agreement 
with this, Csaba and colleagues demonstrated retrograde transport and recycling of 
SSTR-2 in hippocampal neurons. Agonist induced SSTR-2 internalization was achieved 
through rapid endocytosis to early-endosomes, bypassing the low pH compartments it 
accumulated in a perinuclear region consistent with the TGN before slowly recycling 
back to the plasma membrane [109]. Evidence that trafficking to acidic environments 
inhibited transduction in 293/SSTR-2 and -3 cells (Figure 4-9) supports that the 
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 neuronal SSTR-2 trafficking pathway might provide a higher level of transduction than in 
in vitro systems. Additionally, the elongated intracellular route that the virus-SSTR 
complex travels may provide the time necessary for membrane fusion and penetration 
events to occur. 
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 Chapter 6. Discussion 
 
 
Identify the Endocytic Mechanisms and Intracellular Destination of Sst-RBS Entry 
 
In this body of work I demonstrated that MLV and HIV-1 based virion particles 
pseudotyped with the Sst-RBS glycoprotein were trafficked to at least two different 
intracellular compartments in 293 cells expressing SSTR subtypes 2, 3 and 5. Moreover, 
the intracellular environment to which SSTR-5 was directed was more permissive than 
the environment that SSTR-2 and -3 directed viruses. This investigation into receptor 
characteristics is significant in that it directly demonstrates that differences in virus-
receptor trafficking can profoundly influence infection efficiency. Endocytosis of the 
somatostatin receptor subtypes 2, 3 and 5 has previously been shown to be clathrin-
dependent [28, 37]. Yet several lines of evidence suggest that virus bound to SSTR-5 
was internalized by a distinct mechanism than SSTR-2 and -3; moreover, this functional 
difference in endocytosis directly correlated with a higher level of infection. Further 
experiments to address which endocytic mechanism Sst-RBS uses for internalization via 
these receptors, identify which intracellular locations these virus-receptor complexes are 
directed and how they influence virus entry would be beneficial for a complete 
characterization of Sst-RBS mediated entry; as well as determining how useful particular 
endocytic and intracellular pathways may be to targeting gene delivery. 
 
To further investigate the endocytic mechanism of Sst-RBS mediated entry, 
dominant negative (DN) Rab GTPases can be utilized. Rab proteins are members of the 
Ras GTPase superfamily and are the master regulatory elements of endosomal 
transport and vesicular trafficking within cells. They act as guanine nucleotide-dependent 
switches which further recruit cascades of effector molecules [110, 111]. Together these 
mechanisms sort cargo, control the directionality of vesicle movement and govern 
membrane fusion between vesicles [112]. Over 60 Rabs have been identified in humans 
thus far [112]. Rab5, Rab7 and Rab11 especially, have been extensively studied for their 
pivotal roles in endocytosis and have become the defining markers for the early (EE), 
middle/late (LE) and recycling (RE) endosomes, respectively. Cells transiently 
expressing a DN-Rab5 protein have been shown to be defective for fusion of primary 
endocytic vesicles from the plasma membrane with the EEs, and DN-Rab7 prevents the 
fusion of EEs and LEs blocking the pathway to lysosomes. Recently Rab11 depletion 
was shown to inhibit the fusion of REs with the plasma surface [113]. Whereas Influenza 
A virus infection was inhibited by the expression of both DN-Rab5 and DN-Rab7 
(indicating the involvement of the LE) infection of VSV and Semliki Forest virus were 
only inhibited by DN-Rab5 expression indicating the involvement of only the EE 
compartment for these two viruses [114, 115]. Additionally, DN-Rab11 had no effect on 
infection of either Influenza or VSV viruses [114]. From these results I would predict that 
Sst-RBS infection via each SSTR should be inhibited by DN-Rab5 expression; however, 
would expression of DN-Rab7 increase infection via SSTR-2 and -3 by blocking the 
degradative pathway? Also, if the RE is involved in increasing the effective number of 
SSTR-5 receptors, an additional question that might be answered is would inhibiting the 
recycling pathway with DN-Rab11 also inhibit infection via SSTR-5? To test these 
questions, the SSTR-expressing cell lines would be transiently transfected with one of 
the DN-Rab expression plasmids in which the Rab protein is fused with a GFP marker. 
These cell populations (as well as populations transiently transfected with WT Rab 
constructs fused to GFP) would then be exposed to Sst-RBS, WT and VSV G 
pseudotyped MLV particles. At 48 hpi, when β-galactosidase expression is evident, the 
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 cells will be fixed and permeabilized. An anti-β-galactosidase antibody followed by a 
secondary antibody conjugated to Alexa-594 will be used to probe for transfected cells 
so that both GFP and β-galactosidase expression can be visualized simultaneously. At 
least 100 hundred individual cells would then be evaluated for co-expression of GFP and 
β-galactosidase. If transduction is inhibited by the loss of Rab activity, a decrease in the 
number of cells that are both GFP and β-galactosidase positive will be observed 
compared to the WT Rab transfected SSTR-expressing cells. 
 
Dependence on the presence of Rab5 and Rab7 could also be used to investigate 
the endocytic mechanism by which Sst-RBS-SSTR subtypes are internalized. 
Clathrin-mediated endocytosis shows dependence on both Rab5 and Rab7 while 
Caveolin-associated endocytosis only shows dependence on Rab5 [55]. Several 
pathways in addition to clathrin- and caveolin-dependent endocytosis are utilized by 
viruses for the purpose of gaining entry to the intracellular milieu. Of particular interest is 
the macropinocytic pathway which typically involves microtubules, cholesterol, Rab5, 
and Rab7 as well as other cellular processes like Na+/H+ exchange, which decreases 
the pH of pre-lysosomal and lysosomal vesicles. A growing number of viruses have been 
shown to be internalized in macropinosomes including vaccinia virus, adenovirus 
serotype 3, echovirus 1, coxsackivirus B, herpes simples virus 1, and has been 
implicated in HIV-1 infection [116]. Recently, ebola virus was also added to this list [117, 
118]. If infection of Sst-RBS shows dependence on both Rab5 and Rab7 the use of a 
phosphatidylinositol‑3-kinase (PI3K) inhibitor such as wortmannin to inhibit ruffle 
formation might help distinguish clathrin-mediated from macropinosome internalization.  
 
 I demonstrated that there was a significant block to entry of Sst-RBS pseudotyped 
virions via SSTR-2 and -3 which occurred after internalization but prior to reverse 
transcription (Figure 4-11). A block of this type is often seen when virions fail to trigger 
membrane fusion [12, 14, 46]. Membrane fusion of the WT MLV Env is accomplished by 
first binding to its cellular receptor that, in turn, causes conformational changes between 
the TM and SU subunits. Upon internalization, host cell proteases further potentiate 
membrane fusion by cleaving the MLV Env, allowing conversion from a hemi-fusion to a 
fusion state, which subsequently allows pore formation and virion core penetration [7, 8]. 
The Sst-RBS virus is capable of efficient membrane fusion when bound to and 
internalized by SSTR-5, but are the possible fusion defects seen in 293/SSTR-2 and -3 
cells because the correct TM-SU conformation changes were not achieved or because 
the compartment to which these receptor subtypes direct the virions is non-permissive? 
Evidence that virions bound to SSTR-2 and -3 were capable of inducing membrane 
fusion was seen when infection was carried out in the presence of BafA and monensin 
which neutralize endosomal compartments (Figure 4-9); indicating that the block is due 
to the nature of the compartments. Direct demonstration that SSTR-2 and SSTR-3 are 
fusion-competent can be achieved through a cell-cell fusion assay in which mixing of the 
outer leaflet of the cell membrane is compared to cytoplasmic content mixing. Effector 
293 cells exogenously expressing the Sst-RBS glycoprotein and a cytoplasmic dye are 
mixed with target 293/SSTR-expressing cells containing a differently colored cytoplasmic 
dye and DiI, a lipid soluble dye as a membrane marker. In previous infection 
experiments, it was noted numerous times that 293/SSTR-expressing cells do not form 
syncytia in the presence of Sst-RBS virus; however, the cells do show a higher order of 
cell-cell attachment that is typically seen immediately prior to syncytia formation 
(anecdotal evidence). These cell-cell attachments might indicate that the virus is trapped 
in hemi-fusion state and incapable of completing membrane fusion because they have 
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 not been exposed to host proteases. If this is the case, one would expect some degree 
of lipid mixing between the outer plasma membrane of DiI positive target cells and 
negative effector cells. To induce membrane fusion and content mixing, a protease may 
need to be added to the cells as a final trigger. Possible outcomes of this experiment 
might indicate that each SSTR is capable of mediating the same amount of membrane 
fusion after the protease trigger; or alternatively, that Sst-RBS-SSTR-5 complexes are 
more fusigenic. Additionally, while the complexes may be triggered by the same 
protease they might be sufficiently distinct that the protease that triggers the SSTR-5 
complex is different from the protease required by SSTR-2 and -3. If the latter is true 
then identifying which proteases are capable of triggering membrane fusion may also 
provide clues to the intracellular location that each of these receptors directs internalized 
viruses. Knowledge gained from this information would build a better foundation for 
creating viral vectors that match the entry requirements of the targeted entry receptor.  
 
 
Sst-RBS Lentivirus Titers 
 
A particular unexplained observation was that while the Sst-RBS LV titers showed 
the same general trend of transduction in vitro, namely that transduction of 293/SSTR-5 
cells was higher than 293/SSTR-2 and -3 cells, the overall transduction of Sst-RBS LV 
compared to the equivalently pseudotyped MLV was much lower (Figure 4-2). Yet this 
does not seem to translate into low titers during in vivo experiments (Figure 5-6) in the 
mouse brain. This might be due to a relatively low number of glycoprotein spikes 
incorporated by the HIV-1 virion in its membrane. Typically, HIV-1 incorporates between 
8-10 trimers per virion [119]. Others demonstrated that whereas low levels of Env 
incorporation was sufficiently capable of mediating transfection, artificially enhancing the 
amount of Env increased transduction but only to a certain extent [120]. Additionally, 
retrovirus Env pseudotyped LV particles showed limited levels of incorporation [48, 49] 
and transduction [23] which may also be a factor in decreasing the overall LV titers.  
 
A further explanation may be that a host restriction factor is acting on either or both 
the MLV and LV particles. Multiple host restriction factors have been identified and 
characterized in humans, mice and non-human primates with varying restrictive activities 
for retroviruses as well as a number of other viruses. Of the currently identified host 
restriction factors, the most pertinent to the systems described in this research are the 
APOBEC3, TRIM5α, Fv1 and the recently identified Tetherin and SAMHD1 proteins 
[121]. Restriction of viruses by these host factors occurs by one or a combination of the 
following: preventing virion budding, uncoating, reverse transcription of viral RNA, or 
nuclear import/integration mechanisms.  
 
APOBEC3 (Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3) 
proteins belong to the cytidine deaminase family. Humans encode 6 proteins (A, B, C, 
DE, F, G and H) whereas mice encode a single protein. The mouse APOBEC3 protein 
and the human G and F proteins can have restrictive activity on HIV-1 infection. They 
are packaged into virus particles by producer cells and are transferred to target cells 
during infection and inhibit viral replication by cytidine deaminase-dependent 
or -independent mechanisms. In the dependent mechanism, viral cytosines are 
deaminated to generate uracils on newly synthesized minus-strand cDNA. The presence 
of uracils in DNA either triggers DNA repair enzymes to degrade the product or they 
generate G to A hyper-mutations in the copied plus-strand DNA that negatively affect the 
integrity of the viral genomic content [121, 122]. APOBEC3G and F can also reduce the 
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 efficiency of tRNAlys3 priming of the viral RNA and block reverse transcription as well as 
block viral integration in deaminase-independent mechanisms that are not well 
understood [121]. HIV-1 has developed an accessory protein; Vif (viral infectivity factor) 
that is capable of binding APOBEC3 proteins and linking them to E3 ligases which 
induces polyubiquitylation of both APOBEC3 and Vif triggering proteasomal degradation 
[113, 114]. Vif is also capable of blocking APOBEC3 protein from encapsulation by an 
unknown degradation-independent mechanism [121]. Thusly, APOBEC3G and F should 
not be capable of restricting the Vif-positive HIV-1 infection in the human 293-derived 
SSTR-expressing cell lines. Interestingly, Vif activity is species-specific; but HIV-1 Vif 
should also be capable of blocking and counteracting APOBEC3G and F proteins during 
the in vivo mouse experiments because their activity is entirely dependent on packaging 
in virions prior to release. Since the producer cell line (293FT) used to generate the 
Sst-RBS and VSV G pseudotyped LV particles for these experiments is a human line, 
the species-specificity is still guaranteed. Additionally, human APOBEC3 proteins do not 
restrict MLV viruses [122]. 
 
 Tetherin is constitutively expressed on the surface of bone-marrow CD34+ cells as 
well as B and T cells. It is an unusual membrane protein in that it is doubly anchored at 
the cell surface by a glycophosphatidylinositol (GPI) anchor in cholesterol-rich lipid 
microdomains and an α-helical transmembrane domain located outside lipid rafts. 
Tetherin’s restrictive activity most likely derives from a homodimeric structure which 
anchors budding virions via the GPI-anchor at virus assembly sites in lipid microdomains 
and “tethers” them to the surface via the transmembrane domain inhibiting the release of 
the budding virions. The HIV-1 accessory protein U (Vpu) is capable of binding to and 
down-regulating tetherin from cell surfaces possibly by proteasomal degradation [121]. 
The recently described SAMHD1 (sterile alpha motif and histidine-aspartic domain) 
protein is expressed in myeloid cells, T and B cells. It restricts HIV-1 and MLV replication 
by decreasing the intracellular pool of dNTPs in non-dividing cells [121]. However, no 
expression of either of these two host factors has been documented in human 293 cells 
or murine brain cells. 
 
 The human tripartite motif (TRIM)-containing protein 5α isoform shows cross-
species-specific restriction of retroviruses, as this restriction factor does not restrict 
viruses isolated from the same host species (e.g. human TRIM5α does not restrict 
HIV-1). TRIMs have multiple functional domains; an N-terminal RING finger domain, one 
or two B-box domains, a coiled-coil domain and many also have a C-terminal PRYSPRY 
domain. This PRYSPRY domain is essential for interacting with retroviral CA proteins; 
but only when the capsid is in a lattice structure [123]. The RING domain of TRIM5α 
functions as an E3 ubiquitin ligase and the B-box and coiled-coil domains function 
together in protein-protein interactions allowing TRIM5α to multimerize around the 
retroviral CA lattice. The full nature of TRIM5α restriction is still not entirely identified, but 
in its presence restricted retroviral capsid structures are prematurely disassembled and 
the viral reverse transcription complex is proteasomally degraded [121]. Indeed, recently 
TRIM5α was found to associate with PSMC2, a proteasomal subunit, in discrete 
cytoplasmic bodies [124]. While this association occurs in the absence of restricted 
virus, in its presence proteasomal association with TRIM5α cytoplasmic bodies 
increased [125]. There is also evidence to suggest a non-proteasomal action of TRIM5α 
in which TRIM5α blocks restricted CAs from interacting with host machinery and thereby 
blocking nuclear import [126]. As the PRYSPRY domain of human TRIM5α does not 
recognize HIV-1 or Moloney MLV CA proteins, it is unlikely that TRIM5α is restricting 
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 transduction in the SSTR-expressing 293 cells. Although mice do not express TRIM5α, 
they do have a similar host factor termed Friend virus susceptibility factor-1 (Fv1). One 
of three Fv1 alleles (Fv1n, FV1b or FV1nr) are expressed by in-bred mice and they each 
encode a degenerate retroviral Gag protein which binds the N-terminal domain of CA 
from different MLV strains. This interaction restricts MLV infection at a point after reverse 
transcription but before integration; however the action by which this occurs has not 
been elucidated [127]. Neither Moloney MLV nor HIV-1 is restricted by any of the Fv1 
alleles [122].  
 
 Neither the available literature nor the experimental results indicate that a host 
restriction factor might be acting to reduce transduction by SSTR-2 or -3; nevertheless, 
the possibility is not excluded. The issue is of particular relevance if one considers that 
virions associated with SSTR-2 and -3 may not be inactivated in lysosomes as 
proposed, but instead these receptors are sorted to a compartment where membrane 
fusion may be just as efficient as with SSTR-5 and yet uncoating/penetration is still 
somehow restricted. However, this means that the host factor must be specifically 
located and accessible only by certain entry routes, blocking virions entering through 
SSTR-2 and SSTR-3 but not through SSTR-5. If such a host restriction factor is involved 
its identification will require further research efforts such as siRNA mediated knockdown 
of the restriction factors discussed here. Transduction assays could then be performed 
in the presence and absence of each respective host factor and differences in 
transduction evaluated. 
 
 
Targets for Sst-RBS-Mediated Gene Delivery In Vivo 
 
 
SSTR-expressing Tumors 
 
SSTRs have a broad distribution throughout the body. Surface expression of SSTRs 
is abundant in the brain; gastrointestinal tract; exo- and endocrine pancreas and pituitary 
[27, 28]. SSTRs have also been identified on the surface of neuroendocrine tumors 
(NET) [128], breast cancer tumors [129] glial tumors and meningiomas, renal cell 
carcinomas and lymphomas [130]. NETs occur most frequently in the gastrointestinal 
tract (in descending order of frequency: small intestine, rectum, colon, pancreas, 
stomach and appendix) but also in the bronchopulmonary system, ovaries, testes and 
hepato-biliary system with much lower incidences. A majority (70-90%) of NETs express 
multiple SSTRs with SSTR-2 and SSTR-5 subtypes being the most common [128]. 
Similarly, SSTR-2 expression is predominant in breast tumors, however, multiple SSTR 
subtypes are also displayed [129]. Radio- and generator-derived positron emitter-labeled 
somatostatin analogs (SSA) allow visualization of tumor lesions with nuclear imaging 
techniques for diagnosis, tumor localization and grading [128]. SSAs themselves have 
also been used for a variety of treatment outcomes. They have been shown to control 
tumor growth, inhibit the secretion of hormones and growth factors, control 
hormone-related symptoms and in some cases cause tumor shrinkage [131]. 
Additionally, cytotoxic drugs (such as camptothecin, methotrexate, paclitaxel, and 
doxorubicin) conjugated to SSTR-2 specific analogs show positive treatment outcomes 
[132] and Octreotide induced SSTR-2 internalization in NETs has been directly 
demonstrated [133]. However, decreased expression of SSTRs in dedifferentiated 
tumors associated with metastatic states of both NETs and breast cancers have been 
documented [128, 129]. Additionally, target receptor signaling and internalization 
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 pathways may become interrupted in tumor cells [134] suggesting that SSA-related 
diagnosis and treatment has a limited window of efficacy and early diagnosis of patients 
is critical. The addition of Sst-RBS vector treatments transducing any number of 
chemotherapeutic or cytotoxic genes as well as genes rendering tumors susceptible to 
immune clearance may provide another valuable treatment option to clinicians. This 
might prove especially attractive if gene transduction and stable expression occurs 
before tumors begin downregulating SSTRs. 
 
 
Central Nervous System 
 
In chapter 5, I demonstrated proof of principle for Sst-RBS LV transduction in the 
murine brain and showed that SSTR-2 is expressed in several regions of therapeutic 
interest (Figures 5-1 and 5-2). Treatment of neurodegenerative diseases has been 
complicated. Large complexes cannot cross the BBB and most only mask symptoms 
without addressing disease progression or curative treatment. Promising advancements 
have been made in response to this need, however, and I will discuss several that could 
be compatible with Sst-RBS pseudotyped viral vectors.  
 
Neurotrophic factors (NTF) are small (less than 20 kD) secreted proteins that 
regulate neuronal development and maintenance. They include nerve growth factor, 
brain-derived neurotrophic factor, neurotrophin-3 and 4/5, glial cell line-derived factor, 
and neurturin. NTFs have been shown to slow or even prevent neurological disease by 
increasing neuronal metabolism and growth and preventing death from nerve injuries 
and brain traumas. They have been investigated as treatments for multiple conditions 
involving neuronal destruction such as AD, HD and PD, as well as amyotrophic lateral 
sclerosis (ALS), epilepsy, spinal cord injury, neuropathic pain and stroke. Several clinical 
trials using AAV2 and LV vectors to transduce various NTFs for AD and PD treatment 
are underway [135].  
 
RNA interference (RNAi) strategies are another promising avenue for treatment of 
neurodegenerative diseases and cancer. In vitro and preclinical models have revealed 
potential therapeutic targets for ALS, AD, HD, PD and frontotemporal dementia among 
others by selectively targeting mutant genes associated with these conditions. RNAi 
targets for cancer treatments might include selectively targeted oncogenes or genes that 
are involved in radio- or chemotherapy resistance mechanisms. As with all other 
treatment strategies, technical barriers such as specific delivery of therapeutic doses to 
target cells, long-term expression and the inability to cross the BBB are among the most 
significant challenges, but AAV and LV vectors are capable of transducing small 
interfering RNA (siRNA) and short hairpin RNA (shRNA) [136].  
 
Viral vectors to deliver lysosomal enzyme genes such as GUSB have been 
developed for mouse and dog models [137-139] and successful transduction of GUSB in 
the murine brain has been documented using several types of viral vectors by both 
intracranial and intraventricular routes of administration. AAV2 injected into the lateral 
ventricles of an adult mouse brain had limited affect as it was only capable of accessing 
the subarachnoid space and transducing pia-arachnoid and hypothalamus cells [104]. 
Injecting neonatal mice, however, allowed both AAV1 and AAV2 greater access to the 
developing brain and nearly all brain structures were transduced with expression of 
GUSB mRNA lasting for up to year in most cases. Limited transduction, mostly choroid 
plexus and ependymal cells, was seen in AAV5 infected neonatal mice. Neither AAV1 
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 nor AAV2 transduced any glial or oligodendrocyte cells; but instead, AAV-marker 
expressing cells strictly colocalized with a neuron-specific marker. Remarkably, direct 
transduction was not required for protection, as demonstrated by the absence of lesions 
in non-transduced glial and gray matter cells indicating that GUSB had been secreted by 
transduced cells and absorbed by neighboring cells [91]. When a VSV G-pseudotyped, 
HIV-based LV transducing human GUSB was injected into the striatum of adult MPS VII 
mice, GUSB activity was present at injection sites and stable for up to 16 weeks. 
Correction of lysosomal storage lesions was observed in areas showing GUSB activity 
that could be attributed to direct and indirect viral transduction. As in the AAV vector 
studies, improvement was most pronounced in neurons [90]. The most profound report 
of lysosomal lesion correction, however, followed injection of a VSV G LV GUSB vector 
into the lateral ventricles of 6 week old mice. GUSB activity and the presence of 
lysosomal lesions were assayed after 7 months. The authors documented nearly 
complete correction of lesions in all brain sections even though GUSB enzyme activity 
was only significantly detected in one section [140]. These results were presumably due 
to vector delivery into the CSF which was more capable of effective distribution, as 
evidenced by RT-PCR detection of vector in each section. However, this may also 
represent a greater capacity for distribution of secreted enzyme by the CSF originating 
from transduced cells surrounding the ventricular spaces. In either case, delivery to the 
CSF and its associated structures could provide an excellent target for Sst-RBS 
pseudotyped viral vectors.  
 
The choroid plexus (ChP) is an interesting structure located within the ventricular 
spaces of the brain. It is composed of specialized epithelial cells that are folded into villi 
surrounding fenestrated capillaries that project out into the ventricles. These frond-like 
processes filter water and actively transport ions and macromolecules from blood 
plasma to produce CSF. The ChP is responsible for producing, circulating and filtering 
toxic substances from the CSF and brain and proteins expressed by the ChP are 
excreted into the CSF [141, 142]. The ChP forms a continuous structure with the 
ependymal cell layer. Ependymal cells are of a glial cell lineage. Structurally similar to 
cuboidal epithelium cells (they are not true epithelial cells since they do not possess a 
basement membrane or tight junctions), they line the ventricular spaces of the brain and 
central canal of the spinal cord [143]. Their apical surfaces are covered in cilia and 
microvilli which circulate and absorb CSF. Since the ependymal layer does not contain 
tight junctions like the ChP epithelium, CSF and solutes are capable of diffusing through 
this Brain-CSF interface while the ChP epithelial cells maintain the strict BBB [141]. 
Ependymal cells may also serve as a source of neuronal stem cells (NSC) after injury 
[144]. Adult mouse ependymal cells stain positively for all SSTR subtypes, albeit at 
varying intensities and locations [89]. Additionally, I demonstrated SSTR-2 expression 
(Figure 5-4) and transduction by Sst-RBS LV (Figure 5-5). Human ChP epithelial cells 
also stain positively for SSTR-1 and -2 [145]. Thus, the ChP and ependymal cells are 
good candidates for Sst-RBS LVs transducing lysosomal enzymes and NTFs since they 
interact directly with CSF which could deliver these secreted proteins throughout the 
entire brain. 
 
Other targets for CNS delivery are neurogenic regions that contain NSCs capable of 
giving rise to new neurons and glial cells. If NSCs or another progenitor cell could be 
transduced this would provide a source of new neurons that now express the target 
gene. The subventricular zone (SVZ), which is located along the lateral walls of the 
lateral ventricles, and the subgranular zone (SGZ) of the hippocampal dentate gyrus are 
the two known neurogenic regions in the adult mammalian brain. The human SVZ is 
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 composed of four distinct layers: a single layer of ependymal cells lining the ventricle, a 
gap into which the basal projections of the ependymal cells interact with astrocyte 
processes, a layer of astrocyte cell bodies, and finally a transitional zone to the brain 
parenchyma. The SVZ of rodents, dogs and other primates is organized differently in 
that it lacks the hypocellular gap layer separating the ependymal cells from astrocytes 
(which can be subdivided into B1 and B2 cells) and contains many more rapidly dividing 
immature precursor cells (termed C cells) and migrating neuroblasts (termed A cells) 
[94, 146, 147]. The SVZ’s location and cellular population create a “germinal niche” 
providing the vasculature and important cellular signals that support neurogenesis [144, 
148]. The primary progenitor NSCs of the SVZ have been identified as the B1 population 
of astrocyte cells [146]. These GFAP positive cells are derived from the same radial glial 
lineage as ependymal cells [143, 149] and remain in close association with them in the 
SVZ, projecting processes between the ependymal cells and directly contacting the CSF 
of the lateral ventricles forming a “pinwheel” of ependymal cells surrounding the 
astrocyte processes [148, 150]. The B1 cells receive neurogenic signals from the 
components of the germinal niche stimulating them to develop into the transient 
amplifying C cells which then become immature neuroblasts [144, 148, 151]. In the 
rodent SVZ the neuroblasts are supported by the glial sheaths of the B2-type astroctyes 
and form long chains that migrate along the rostral migratory stream (RMS) to the 
olfactory bulb where they finally mature [144]. While NSCs have been isolated from the 
adult human SVZ, the existence of the RMS to olfactory bulb pathway has been a 
source of debate. Recently, however, it was discovered that migrating neuroblasts are 
found along the RMS; but as single or double cells, not in long chains as in the rodent 
RMS [152]. Aside from ependymal cells, the expression of SSTRs on other SVZ cell 
types has not been documented. If they do express SSTRs this neurogenic region 
presents an intriguing target cell population. Because they migrate long distances from 
their location of genesis (and possibly transduction) they have an opportunity to deliver 
secreted proteins not only at their final destination but along the RMS as well.  
 
The second area of neurogenesis in the adult brain is the SGZ. In this region of the 
hippocampus, radial glial-like precursors first develop into neuronal progenitor cells and 
then neuroblasts which migrate throughout the granular layer of the dentate gyrus. To 
become mature granular cells the new neurons extend dendrites towards the molecular 
layer and project axons through the hilus into the CA3 region of the hippocampus. The 
dentate gyrus is strongly positive for SSTR-2 expression (Figure 5-2B) and SSTR-1 and 
SSTR-2 are also expressed in the CA3 region [153]. As the hippocampus is one of the 
first regions showing neurodegenerative damage in AD [154], these regions could be 
excellent candidates for Sst-RBS targeted viral vectors transducing NTFs. 
 
 
Conclusion 
 
I demonstrated that a modified MLV glycoprotein, Sst-RBS, has a transduction 
capacity comparable to that of the WT MLV Env and approaches that of VSV G, the 
“gold standard” in transduction efficiency in in vitro transduction assays (Figures 3-1 and 
4-2). I observed that only one Sst-RBS target receptor subtype, SSTR-5, was capable of 
reaching this level of transduction, evidently because other receptors tested delivered 
virions to degradative environments (Figures 4-9 and 4-10) that were less permissive for 
entry; whereas SSTR-5 associated virions were directed to more permissive 
compartments that allowed efficient cytosolic penetration (Figure 4-11). Yet, in vivo 
transduction assays carried out in the murine brain did not seem to correlate with the in 
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 vitro data as transduction of both Sst-RBS and VSV G pseudotyped LV vectors was 
similar (Figures 5-6 and 5-7).  
 
During the course of investigating the transduction capacity of Sst-RBS and its 
potential for use as an in vitro gene delivery vector, the area of vector diffusion was 
measured for Sst-RBS and VSV G Envs. Interestingly, Sst-RBS showed a greater 
potential for vector diffusion than VSV G in which transduction was generally 
concentrated in a small core area (Figure 5-7). This is a significant observation because 
delivering therapeutics to brain cells may be more effective if a gene can be delivered to 
a larger overall area, rather than high transduction in a very small area. For example, 
genes that encode secreted proteins such as deficient lysosomal enzymes or 
neurotrophic factors will generate a higher level of therapeutic benefit in this situation 
because a greater area is covered using fewer vectors. Additionally, since the proteins 
are secreted, non-transduced cells in the transduction zone also benefit. The coding 
sequences of the deficient enzymes causing lysosomal storage diseases are less than 
5000 base pairs, well within the capacity limits of LV. 
 
SSTR-2 receptor expression was observed in neurons and ependymal cells 
(Figures 5-3 through 5-5) making these cells types potential targets for gene 
transduction by Sst-RBS coated viral vectors. Moreover, delivery of the transduction 
marker mKate2 was demonstrated in ependymal cells. Because the ependymal cells line 
the ventricles of the brain, they are in close association with the CSF which provides 
another intriguing delivery route. Since the CSF is naturally distributed throughout the 
CNS; proteins secreted into the CSF by ependymal cells could potentially gain access all 
neurological cell types. In the current study, transduction was achieved through direct 
injection into the murine brain parenchyma. However, this highly invasive method of 
delivery is not feasible in humans. Less invasive delivery methods exist to access the 
CSF including spinal taps and intrathecal catheters making delivery to the CSF and its 
associated structures (the ependymal and choroid plexus cells) an even more attractive 
option.  
 
One of the more interesting questions remaining after these studies is that of 
identifying the intracellular compartments to which SSTR-2, -3 and -5 direct the Sst-RBS 
virus in culture. Using DN-Rab proteins and fluorescent microscopy this information 
could easily be obtained. Yet, the dramatic difference in transduction capacity between 
SSTR-2 and SSTR-5 expressing cells did not translate into a similarly low transduction 
capacity in vivo. This difference may actually represent a cell culture artifact and 
therefore more useful information would be obtained by concentrating experimental 
resources on in vivo studies. Moreover, additional information pertaining to in vivo 
transduction, beyond that generated during this preliminary investigation needs to be 
attained. First, the sample sizes for transduction and diffusion zone areas should be 
greater so that large variations due to the nature of individual animals can mitigated. 
Second, more definitive proof that transduction is SSTR specific should be obtained. 
Competition assays between Sst-RBS and VSV G pseudotyped vectors in the presence 
and absence of the inhibitory peptide, SST-14, may be able to answer this question. 
Third, greater detail regarding the expression of other SSTR subtypes in neurological 
cell types should be generated. Monoclonal antibodies specific to each of these receptor 
subtypes can be obtained and immunohistochemical staining protocols similar to those 
here can be used. In conclusion, demonstrating proof of principle for in vivo gene 
transduction by the modified retroviral glycoprotein, Sst-RBS, is certainly an exciting 
advance in the gene therapy field.   
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